



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 174 510 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
23.01.2002 Bulletin 2002/04

(51) Int Cl.7: C12N 15/61, C12N 15/29,
C12N 15/82, C12N 9/90,
A01H 5/00

(21) Application number: 01306143.7

(22) Date of filing: 17.07.2001

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU

MC NL PT SE TR

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: 17.07.2000 US 218712 P

(71) Applicant: E.I. du Pont de Nemours and Company
Wilmington, Delaware 19880-0024 (US)

(72) Inventors:

• Allen, Stephen M.
Wilmington, Delaware 19810 (US)

• Butler, Karlene H.
Newark, Delaware 19713 (US)
• Carlson, Thomas J.
Ann Arbor, Michigan 48105 (US)
• Ilag, Lawrence L.
Greenville, Delaware 19807 (US)

(74) Representative: Matthews, Derek Peter
Frank B. Dehn & Co., European Patent Attorneys,
179 Queen Victoria Street
London EC4V 4EL (GB)

(54) Plastidial phosphoglucomutase genes

(57) This invention relates to an isolated nucleic acid fragment encoding a plastidic phosphoglucomutase protein. The invention also relates to the construction of a chimeric gene encoding all or a substantial portion of

the plastidic phosphoglucomutase, in sense or anti-sense orientation, wherein expression of the chimeric gene results in production of altered levels of the plastidic phosphoglucomutase in a transformed host cell.

FIGURE 1

SEQ ID NO: 12	1	MAF-----CY-RLDN-FIISAFKPKHNSVPLSI-----HHSS--SNFPSFKVQNFPFR
SEQ ID NO: 13	1	MAF-----CY-RLDN-FIISAFKPKHNSVPLSI-----HHSS--SNFPSFKVQNFPFR
SEQ ID NO: 08	1	MAF-----SC-KLDS-FIISAYKPQNSILPLSI-----QPSSTLPSPSPLSLKPQKLPFR
SEQ ID NO: 04	1	M-----PTM-----HALRLCPLL--
SEQ ID NO: 10	1	TRLARFLPRCKRNTTSPHSPSRLFSPSPPPPLSLSAWRWHCRPPHRLGMASHALRLHPLLFS
SEQ ID NO: 02	1	AP-ARY----RHL3LSQSLSPYL-----QEMAMSVEVTMRLLHPLVPS
SEQ ID NO: 11	1	MSS-----TYARFDTVFLLSRF-AGAKYSPLWP-----SSSS--SSHSSLSSGFIHLR
		60
	1	

* * * * *

SEQ ID NO: 12	45	VRYNSAIRATSSSSSTPTT--IA-----EPNDIKINSIPTKPIEGQ
SEQ ID NO: 13	45	VRYNSAIRATSSSSSTPTT--IA-----EPNDIKINSIPTKPIEGQ
SEQ ID NO: 08	47	IRYGSTIRATSSSSTPSAT--IA-----EPEGIKIKSIPTKPIDGQ
SEQ ID NO: 04	14	-STIRSTP--PRATAARQ--G--AL-FVARCSSAGTFSAAQALKISSIPTKPVEGQ
SEQ ID NO: 10	61	AAAARPAPLAARPGGGARR--VHRRHSL-AVVRCCS---SAAQALKIKSIPTKPVEGQ
SEQ ID NO: 02	37	SKLLSPSSSSPAVLVSSRIPLLSLRPNLRFSVKATASSTPSTAESIKIKSIPTKPVEGQ
SEQ ID NO: 11	46	AKPNSRLRSVTGASSSSSGPITA-----GSESIEIKSLPTKPIEGQ
	61	120

* * * * *

SEQ ID NO: 12	84	KTGTSGLRKKVVKVFKQENYLANWIQALENSLPPEDYKNGLLVLGGDGRYFNKEAAQIIIK
SEQ ID NO: 13	84	KTGTSGLRKKVVKVFKQENYLANWIQALENSLPPEDYKNGLLVLGGDGRYFNKEAAQIIIK
SEQ ID NO: 08	86	KTGTSGLRKKVVKVFMQDNYLANWIQALENSLPPEDYKNGLLVLGGDGRYFNKEAAQIIIK
SEQ ID NO: 04	63	KTGTSGLRKKVVKVFKQENYLANWIQALENSLPPEDYVGGTLVLGGDGRYFNKEAAQIIIK
SEQ ID NO: 10	113	KTGTSGLRKKVVKVFKQENYLANWIQALENSLPPEDYVGGTLVLGGDGRYFNKEAAQIIIK
SEQ ID NO: 02	97	KTGTSGLRKKVVKVFKQENYLANWIQALENSLPLEDYKNGLLVLGGDGRYFNKEAAQIIIK
SEQ ID NO: 11	87	KTGTSGLRKKVVKVFMQDNYLANWIQALENSLPLEDYKDATVLGGDGRYFNKEAAQIIIK
	121	180

Description

[0001] This application claims the benefits of U.S. Provisional Application No. 60/218,712, filed July 17, 2000, the entire contents of which are herein incorporated by reference.

5

FIELD OF THE INVENTION

[0002] This invention is in the field of plant molecular biology. More specifically, this invention pertains to nucleic acid fragments encoding plastidic phosphoglucomutase proteins in plants and seeds.

10

BACKGROUND OF THE INVENTION

[0003] Starch synthesis occurs in the chloroplast while soluble carbohydrate (i.e., sucrose) synthesis occurs in the cytosol. These biosynthetic pathways are competing processes because excess triose phosphate can be used for either starch synthesis in the chloroplast or sucrose synthesis in the cytosol. These pathways have many common steps, however, the enzymes that catalyze similar steps are unique to each compartment. These enzymes are isozymes; different forms of the enzymes that catalyze the same reaction. For example, the plastidic and cytosolic forms of phosphoglucomutase both catalyze the conversion of glucose-6-phosphate to glucose 1-phosphate in different sub-cellular locations.

20

[0004] At maturity, about 40% of soybean seed dry weight is protein and 20% extractable oil. These constitute the economically valuable products of the soybean crop. Of the remaining 40% of seed weight, about 10% is soluble carbohydrate. The soluble carbohydrate portion contributes little to the economic value of soybean seeds and the main component of the soluble carbohydrate fraction, raffnosaccharides, are deleterious both to processing and to the food value of soybean meal in monogastric animals (Coon et al., (1988) *Proceedings Soybean Utilization Alternatives*, Univ. of Minnesota, pp. 203-211).

25

[0005] It may be possible to modulate the size of the starch and soluble carbohydrate pools in plant cells by altering the catalytic activity of specific enzymes (i.e., phosphoglucomutase) in the starch and soluble carbohydrate biosynthetic pathways (Taiz L., et al, *Plant Physiology*; The Benjamin/Cummings Publishing Company: New York, 1991). For example, during soybean seed maturation a large portion of the glucose which is converted to soluble carbohydrates (sucrose, raffinose and stachyose) during soybean seed maturation comes from the break down of a starch pool which was produced slowly during the primary growth phase. Elimination of this transient starch pool may be a strategy for diverting carbon away from the soluble carbohydrate components of dry soybean seeds (sucrose, raffinose and stachyose) and into the more economically desirable components such as oil and protein. This strategy may also be applicable to other plants such as corn, rice and wheat.

35

[0006] There is a great deal of interest in identifying the genes that encode proteins involved in starch and soluble carbohydrate biosynthesis in plants. The genes that code for these enzymes may be used to study the interactions among individuals of the pathways and develop methods to alter starch and soluble carbohydrate biosynthesis. Accordingly, the availability of nucleic acid sequences encoding all or a substantial portion of a plastidic or cytosolic phosphoglucomutase enzyme would facilitate studies to better understand starch and soluble carbohydrate biosynthesis in plants and provide genetic tools to enhance or otherwise alter starch and soluble carbohydrate biosynthesis.

40

[0007] The *rug3* locus of *Pisum sativum* encodes the pea plastidic phosphoglucomutase (EP 1001029A1, the entire contents of which are herein incorporated by reference). Pea seeds, of the *rug3/rug3* genotype, substantially lacking plastidic phosphoglucomutase activity, have higher levels of sucrose at the end of the vining period (EP 1001029A1). High-sucrose soybean lines are known to have better industrial processing and food flavor qualities, in the production of soy protein. Consequently, decreasing or eliminating expression of the plastidic phosphoglucomutase gene in soybeans would be desirable for industrial preparation of soy protein.

45

SUMMARY OF THE INVENTION

50

[0008] The present invention concerns an isolated polynucleotide comprising: (a) a first nucleotide sequence encoding a first polypeptide comprising at least 560 amino acids, wherein the amino acid sequence of the first polypeptide and the amino acid sequence of SEQ ID NO:8 have at least 95% identity based on the Clustal alignment method, (b) a second nucleotide sequence encoding a second polypeptide comprising at least 560 amino acids, wherein the amino acid sequence of the second polypeptide and the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:10 have at least 85%, 90%, or 95% identity based on the Clustal alignment method, or (c) the complement of the first or second nucleotide sequence, wherein the complement and the first or second nucleotide sequence contain the same number of nucleotides and are 100% complementary. The first polypeptide preferably comprises the amino acid sequence of SEQ ID NO:8, and the second polypeptide preferably comprises the amino acid sequence of SEQ ID NO:

2, SEQ ID NO:4, or SEQ ID NO:10. The first nucleotide sequence preferably comprises the nucleotide sequence of SEQ ID NO:7, the second nucleotide sequence preferably comprises the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO:3, or SEQ ID NO:9. The first and second polypeptides preferably are phosphoglucomutase,

5 [0009] In a second embodiment, the present invention relates to a chimeric gene comprising any of the isolated polynucleotides of the present invention operably linked to a regulatory sequence, and a cell, a plant, and a seed comprising the chimeric gene.

[0010] In a third embodiment, the present invention relates to a vector comprising any of the isolated polynucleotides of the present invention.

10 [0011] In a fourth embodiment, the present invention relates to an isolated polynucleotide fragment comprising a nucleotide sequence comprised by any of the polynucleotides of the present invention, wherein the nucleotide sequence contains at least 30, 40, or 60 nucleotides.

[0012] In a fifth embodiment, the present invention relates to a method for transforming a cell comprising transforming a cell with any of the isolated polynucleotides of the present invention, and the cell transformed by this method. Advantageously, the cell is eukaryotic, e.g., a yeast or plant cell, or prokaryotic, e.g., a bacterium.

15 [0013] In a sixth embodiment, the present invention relates to a method for producing a transgenic plant comprising transforming a plant cell with any of the isolated polynucleotides of the present invention and regenerating a plant from the transformed plant cell, the transgenic plant produced by this method, and the seed obtained from this transgenic plant.

20 [0014] In a seventh embodiment, the present invention concerns an isolated polypeptide comprising: (a) a first amino acid sequence comprising at least 560 amino acids, wherein the first amino acid sequence and the amino acid sequence of SEQ ID NO:8 have at least 95 % identity based on the Clustal alignment method, and (b) a second amino acid sequence comprising at least 560 amino acids, wherein the second amino acid sequence and the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:10 have at least 85 %, 90%, or 95 % identity based on the Clustal alignment method. The first amino acid sequence preferably comprises the amino acid sequence of SEQ ID NO:8, and the second amino acid sequence preferably comprises the amino acid sequence SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:10. The polypeptide preferably is a phosphoglucomutase.

[0015] In an eighth embodiment, the present invention relates to a virus, preferably a baculovirus, comprising any of the isolated polynucleotides of the present invention or any of the chimeric genes of the present invention.

30 [0016] In a ninth embodiment, the invention relates to a method of selecting an isolated polynucleotide that affects the level of expression of a phosphoglucomutase protein or enzyme activity in a host cell, preferably a plant cell, the method comprising the steps of:

(a) constructing an isolated polynucleotide of the present invention or an isolated chimeric gene of the present invention; (b) introducing the isolated polynucleotide or the isolated chimeric gene into a host cell; (c) measuring the level of the phosphoglucomutase protein or enzyme activity in the host cell containing the isolated polynucleotide; and (d) comparing the level of the phosphoglucomutase protein or enzyme activity in the host cell containing the isolated polynucleotide with the level of the phosphoglucomutase protein or enzyme activity in the host cell that does not contain the isolated polynucleotide.

35 [0017] In a tenth embodiment, the invention concerns a method of obtaining a nucleic acid fragment encoding a substantial portion of a phosphoglucomutase protein, preferably a plant phosphoglucomutase protein, comprising the steps of: synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least 30 contiguous nucleotides, preferably at least 40 contiguous nucleotides, most preferably at least 60 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, and 9, and the complement of such nucleotide sequences; and amplifying a nucleic acid fragment (preferably a cDNA inserted in a cloning vector) using the oligonucleotide primer. The amplified nucleic acid fragment preferably will encode a substantial portion of a phosphoglucomutase protein amino acid sequence.

45 [0018] In an eleventh embodiment, this invention relates to a method of obtaining a nucleic acid fragment encoding all or a substantial portion of the amino acid sequence encoding a phosphoglucomutase protein comprising the steps of: probing a cDNA or genomic library with an isolated polynucleotide of the present invention; identifying a DNA clone that hybridizes with an isolated polynucleotide of the present invention; isolating the identified DNA clone; and sequencing the cDNA or genomic fragment that comprises the isolated DNA clone.

50 [0019] In a twelfth embodiment, this invention concerns a method for positive selection of a transformed cell comprising: (a) transforming a host cell with the chimeric gene of the present invention or an expression cassette of the present invention; and (b) growing the transformed host cell, preferably a plant cell, such as a monocot or a dicot, under conditions which allow expression of the phosphoglucomutase polynucleotide in an amount sufficient to complement a null mutant to provide a positive selection means.

55 [0020] In a thirteenth embodiment, this invention relates to a method of altering the level of expression of a phosphoglucomutase protein in a host cell comprising: (a) transforming a host cell with a chimeric gene of the present invention; and (b) growing the transformed host cell under conditions that are suitable for expression of the chimeric

gene wherein expression of the chimeric gene results in production of altered levels of the phosphoglucomutase protein in the transformed host cell.

[0021] In a fourteenth embodiment, this invention relates to a method for suppressing in a plant the level of expression of a gene encoding a polypeptide having plastidic phosphoglucomutase activity, wherein the method comprises transforming a plant with the fragment of the fourth embodiment.

BRIEF DESCRIPTION OF THE DRAWING AND SEQUENCE LISTING

[0022] The invention can be more fully understood from the following detailed description and the accompanying Drawing and Sequence Listing which form a part of this application.

[0023] Figure 1 shows an alignment of the amino acid sequences of plastidic phosphoglucomutase encoded by the nucleotide sequences derived from the following: cattail clone etr1c.pk005.f8 (SEQ ID NO:2); corn contig (SEQ ID NO: 4) composed of p0075.cslaf22f(EST), p0075.cslaf22rb (EST), and p0128.cpicz81r (EST); soybean contig (SEQ ID NO: 8) composed of clone sdp3c.pk003.e22 and PCR fragments; rice clone rdilc.pk001.a22 (SEQ ID NO:10); plastidic phosphoglucomutase from *Brassica napus* (NCBI Identifier No. gi 6272125; SEQ ID NO:11); plastidic phosphoglucomutase from *Pisum sativum* (NCBI Identifier No. gi 6272283; SEQ ID NO:12); and plastidic phosphoglucomutase from *Pisum sativum* described in European Patent Application EP 1001029-A (NCBI Identifier No. gi 10190529; SEQ ID NO: 13). For the consensus alignment, amino acids which are conserved among all sequences at a given position, and which are contained in at least two sequences, are indicated with an asterisk (*). Dashes are used by the program to maximize alignment of the sequences. Amino acid positions for a given SEQ ID NO are given to the left of the corresponding line of sequence. Amino acid positions for the consensus alignment are given below each section of sequence.

[0024] Table 1 lists the polypeptides that are described herein, the designation of the cDNA clones that comprise the nucleic acid fragments encoding polypeptides representing all or a substantial portion of these polypeptides, and the corresponding identifier (SEQ ID NO:) as used in the attached Sequence Listing. Table 1 also identifies the cDNA clones as individual ESTs ("EST"), the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), contigs assembled from two or more ESTs ("Contig"), contigs assembled from an FIS and one or more ESTs ("Contig*"), or sequences encoding the entire or functional protein derived from an FIS, a contig, an EST and PCR, or an FIS and PCR ("CGS"). Nucleotide SEQ ID NOs:1, 3, 5, and 7 correspond to nucleotide SEQ ID NOs:1, 3, 5, and 7, respectively, presented in U.S. Provisional Application No. 60/218,712, filed July 17, 2000. Amino acid SEQ ID NOs: 2, 4, 6, and 8 correspond to amino acid SEQ ID NOs:2, 4, 6, and 8, respectively, presented in U.S. Provisional Application No. 60/218,712, filed July 17, 2000. The sequence descriptions and Sequence Listing attached hereto comply with the rules governing nucleotide and/or amino acid sequence disclosures in patent applications as set forth in 37 C.F.R. § 1.821-1.825.

TABLE 1

Plastidic Phosphoglucomutase Proteins					
			SEQ ID NO:		
40	Protein (Plant Source)	Clone Designation	Status	(Nucleotide)	(Amino Acid)
	Plastidic Phosphoglucomutase (Cattail)	etr1c.pk005.f8 (FIS)	CGS	1	2
45	Plastidic Phosphoglucomutase (Corn)	Contig Composed of: p0075.cslaf22f (EST); p0075.cs1af22rb (EST); p0128.cpicz81r (EST)	CGS	3	4
	Plastidic Phosphoglucomutase (Rice)	rth1c.pk009.k14.f (EST)	EST	5	6
50	Plastidic Phosphoglucomutase (Soybean)	Contig Composed of: sdp3c.pk003.c22 (EST); PCR Fragments	CGS	7	8
55	Plastidic Phosphoglucomutase (Rice)	rdilc.pk001.a22 (FIS)	CGS	9	10

[0025] SEQ ID NO: 10 corresponds to a direct translation of the nucleotide sequence for the full insert of rice clone rdilc.pk001.a22. The amino acid sequence in SEQ ID NO:10 includes a 46 amino acid open-reading frame directly in

front of, and in frame with, the methionine start codon.

[0026] SEQ ID NO: 11 corresponds to plastidic phosphoglucomutase from *Brassica napus* (NCBI Identifier No. gi 6272125).

[0027] SEQ ID NO:12 corresponds to plastidic phosphoglucomutase from *Pisum sativum* (NCBI Identifier No. gi 6272283).

[0028] SEQ ID NO:13 corresponds to and plastidic phosphoglucomutase from *Pisum sativum* described in European Patent Application EP 1001029-A (NCBI Identifier No. gi 10190529).

[0029] SEQ ID NO:14 corresponds to a 574 nucleotide Ntll fragment from plasmid pTC103, this fragment contains a 541 nucleotide region of soybean plastidic phosphoglucomutase, a 19 nucleotide artificial sequence at the 5' end and a 14 nucleotide artificial sequence at the 3' end.

[0030] SEQ ID NO:15 corresponds to the 541 nucleotide region of soybean plastidic phosphoglucomutase contained in SEQ ID NO:14.

[0031] SEQ ID NO:16 corresponds to the full-insert sequence (FIS) of corn clone p0075.cslaf22rb.

[0032] SEQ ID NO:17 corresponds to the nucleotide sequence of plasmid pKS133.

[0033] The Sequence Listing contains the one letter code for nucleotide sequence characters and the three letter codes for amino acids as defined in conformity with the IUPAC-IUBMB standards described in *Nucleic Acids Res.* 13: 3021-3030 (1985) and in the *Biochemical J.* 219 (No. 2):345-373 (1984) which are herein incorporated by reference. The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.

DETAILED DESCRIPTION OF THE INVENTION

[0034] In the context of this disclosure, a number of terms shall be utilized. The terms "polynucleotide", "polynucleotide sequence", "nucleic acid sequence", and "nucleic acid fragment"/"isolated nucleic acid fragment" are used interchangeably herein. These terms encompass nucleotide sequences and the like. A polynucleotide may be a polymer of RNA or DNA that is single- or double-stranded, that optionally contains synthetic, non-natural or altered nucleotide bases. A polynucleotide in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA, synthetic DNA, or mixtures thereof. An isolated polynucleotide of the present invention may include at least 30 contiguous nucleotides, preferably at least 40 contiguous nucleotides, most preferably at least 60 contiguous nucleotides derived from SEQ ID NOs:1, 3,5,7 and 9, or the complement of such sequences.

[0035] The term "isolated" refers to materials, such as nucleic acid molecules and/or proteins, which are substantially free or otherwise removed from components that normally accompany or interact with the materials in a naturally occurring environment. Isolated polynucleotides may be purified from a host cell in which they naturally occur. Conventional nucleic acid purification methods known to skilled artisans may be used to obtain isolated polynucleotides.

[0036] The term "recombinant" means, for example, that a nucleic acid sequence is made by an artificial combination of two otherwise separated segments of sequence, e.g., by chemical synthesis or by the manipulation of isolated nucleic acids by genetic engineering techniques.

[0037] As used herein, "contig" refers to a nucleotide sequence that is assembled from two or more constituent nucleotide sequences that share common or overlapping regions of sequence homology. For example, the nucleotide sequences of two or more nucleic acid fragments can be compared and aligned in order to identify common or overlapping sequences. Where common or overlapping sequences exist between two or more nucleic acid fragments, the sequences (and thus their corresponding nucleic acid fragments) can be assembled into a single contiguous nucleotide sequence.

[0038] As used herein, "substantially similar" refers to nucleic acid fragments wherein changes in one or more nucleotide bases results in substitution of one or more amino acids, but do not affect the functional properties of the polypeptide encoded by the nucleotide sequence. "Substantially similar" also refers to nucleic acid fragments wherein changes in one or more nucleotide bases does not affect the ability of the nucleic acid fragment to mediate alteration of gene expression by gene silencing through for example antisense or co-suppression technology. "Substantially similar" also refers to modifications of the nucleic acid fragments of the instant invention such as deletion or insertion of one or more nucleotides that do not substantially affect the functional properties of the resulting transcript vis-à-vis the ability to mediate gene silencing or alteration of the functional properties of the resulting protein molecule. It is therefore understood that the invention encompasses more than the specific exemplary nucleotide or amino acid sequences and includes functional equivalents thereof. The terms "substantially similar" and "corresponding substantially" are used interchangeably herein.

[0039] Substantially similar nucleic acid fragments may be selected by screening nucleic acid fragments representing subfragments or modifications of the nucleic acid fragments of the instant invention, wherein one or more nucleotides are substituted, deleted and/or inserted, for their ability to affect the level of the polypeptide encoded by the unmodified

nucleic acid fragment in a plant or plant cell. For example, a substantially similar nucleic acid fragment representing at least 30 contiguous nucleotides, preferably at least 40 contiguous nucleotides, most preferably at least 60 contiguous nucleotides derived from the instant nucleic acid fragment can be constructed and introduced into a plant or plant cell. The level of the polypeptide encoded by the unmodified nucleic acid fragment present in a plant or plant cell exposed to the substantially similar nucleic fragment can then be compared to the level of the polypeptide in a plant or plant cell that is not exposed to the substantially similar nucleic acid fragment.

[0040] For example, it is well known in the art that antisense suppression and co-suppression of gene expression may be accomplished using nucleic acid fragments representing less than the entire coding region of a gene, and by using nucleic acid fragments that do not share 100% sequence identity with the gene to be suppressed. Moreover, alterations in a nucleic acid fragment which result in the production of a chemically equivalent amino acid at a given site, but do not effect the functional properties of the encoded polypeptide, are well known in the art. Thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a functionally equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the polypeptide molecule would also not be expected to alter the activity of the polypeptide. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products. Consequently, an isolated polynucleotide comprising a nucleotide sequence of at least 30 contiguous nucleotides, preferably at least 40 contiguous nucleotides, most preferably at least 60 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, and 9, and the complement of such nucleotide sequences may be used in methods of selecting an isolated polynucleotide that affects the expression of a plastidic phosphoglucomutase polypeptide in a host cell. A method of selecting an isolated polynucleotide that affects the level of expression of a polypeptide in a virus or in a host cell (eukaryotic, such as plant or yeast, prokaryotic such as bacterial) may comprise the steps of: constructing an isolated polynucleotide of the present invention or a chimeric gene of the present invention; introducing the isolated polynucleotide or the chimeric gene into a host cell; measuring the level of a polypeptide or enzyme activity in the host cell containing the isolated polynucleotide; and comparing the level of a polypeptide or enzyme activity in the host cell containing the isolated polynucleotide with the level of a polypeptide or enzyme activity in a host cell that does not contain the isolated polynucleotide.

[0041] Moreover, substantially similar nucleic acid fragments may also be characterized by their ability to hybridize. Estimates of such homology are provided by either DNA-DNA or DNA-RNA hybridization under conditions of stringency as is well understood by those skilled in the art (Hames and Higgins, Eds. (1985) *Nucleic Acid Hybridisation*, IRL Press, Oxford, U.K.). Stringency conditions can be adjusted to screen for moderately similar fragments, such as homologous sequences from distantly related organisms, to highly similar fragments, such as genes that duplicate functional enzymes from closely related organisms. Post-hybridization washes determine stringency conditions. One set of preferred conditions uses a series of washes starting with 6X SSC, 0.5% SDS at room temperature for 15 min, then repeated with 2X SSC, 0.5% SDS at 45°C for 30 min, and then repeated twice with 0.2X SSC, 0.5% SDS at 50°C for 30 min. A more preferred set of stringent conditions uses higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2X SSC, 0.5% SDS was increased to 60°C. Another preferred set of highly stringent conditions uses two final washes in 0.1 X SSC, 0.1% SDS at 65°C.

[0042] Substantially similar nucleic acid fragments of the instant invention may also be characterized by the percent identity of the amino acid sequences that they encode to the amino acid sequences disclosed herein, as determined by algorithms commonly employed by those skilled in this art. Suitable nucleic acid fragments (isolated polynucleotides of the present invention) encode polypeptides that are at least about 70% identical, preferably at least about 80% identical to the amino acid sequences reported herein. Preferred nucleic acid fragments encode amino acid sequences that are about 85% identical to the amino acid sequences reported herein. More preferred nucleic acid fragments encode amino acid sequences that are at least about 90% identical to the amino acid sequences reported herein. Most preferred are nucleic acid fragments that encode amino acid sequences that are at least about 95% identical to the amino acid sequences reported herein. Suitable nucleic acid fragments not only have the above identities but typically encode a polypeptide having at least 50 amino acids, preferably at least 100 amino acids, more preferably at least 150 amino acids, still more preferably at least 200 amino acids, and most preferably at least 250 amino acids. Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS*. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5.

[0043] A "substantial portion" of an amino acid or nucleotide sequence comprises an amino acid or a nucleotide sequence that is sufficient to afford putative identification of the protein or gene that the amino acid or nucleotide

sequence comprises. Amino acid and nucleotide sequences can be evaluated either manually by one skilled in the art, or by using computer-based sequence comparison and identification tools that employ algorithms such as BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also www.ncbi.nlm.nih.gov/BLAST/). In general, a sequence often or more contiguous amino acids or thirty or more contiguous nucleotides is necessary in order to putatively identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene. Moreover, with respect to nucleotide sequences, gene-specific oligonucleotide probes comprising 30 or more contiguous nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., *in situ* hybridization of bacterial colonies or bacteriophage plaques). In addition, short oligonucleotides of 12 or more nucleotides may be used as amplification primers in PCR in order to obtain a particular nucleic acid fragment comprising the primers. Accordingly, a "substantial portion" of a nucleotide sequence comprises a nucleotide sequence that will afford specific identification and/or isolation of a nucleic acid fragment comprising the sequence. The instant specification teaches amino acid and nucleotide sequences encoding polypeptides that comprise one or more particular plant proteins. The skilled artisan, having the benefit of the sequences as reported herein, may now use all or a substantial portion of the disclosed sequences for purposes known to those skilled in this art.

Accordingly, the instant invention comprises the complete sequences as reported in the accompanying Sequence Listing, as well as substantial portions of those sequences as defined above.

[0044] "Codon degeneracy" refers to divergence in the genetic code permitting variation of the nucleotide sequence without effecting the amino acid sequence of an encoded polypeptide. Accordingly, the instant invention relates to any nucleic acid fragment comprising a nucleotide sequence that encodes all or a substantial portion of the amino acid sequences set forth herein. The skilled artisan is well aware of the "codon bias" exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a nucleic acid fragment for improved expression in a host cell, it is desirable to design the nucleic acid fragment such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

[0045] "Synthetic nucleic acid fragments" can be assembled from oligonucleotide building blocks that are chemically synthesized using procedures known to those skilled in the art. These building blocks are ligated and annealed to form larger nucleic acid fragments which may then be enzymatically assembled to construct the entire desired nucleic acid fragment. "Chemically synthesized", as related to a nucleic acid fragment, means that the component nucleotides were assembled *in vitro*. Manual chemical synthesis of nucleic acid fragments may be accomplished using well established procedures, or automated chemical synthesis can be performed using one of a number of commercially available machines. Accordingly, the nucleic acid fragments can be tailored for optimal gene expression based on optimization of the nucleotide sequence to reflect the codon bias of the host cell. The skilled artisan appreciates the likelihood of successful gene expression if codon usage is biased towards those codons favored by the host. Determination of preferred codons can be based on a survey of genes derived from the host cell where sequence information is available.

[0046] "Gene" refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. "Native gene" refers to a gene as found in nature with its own regulatory sequences. "Chimeric gene" refers any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature. "Endogenous gene" refers to a native gene in its natural location in the genome of an organism. A "foreign gene" refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes. A "trans-gene" is a gene that has been introduced into the genome by a transformation procedure.

[0047] "Coding sequence" refers to a nucleotide sequence that codes for a specific amino acid sequence. "Regulatory sequences" refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, and polyadenylation recognition sequences.

[0048] "Promoter" refers to a nucleotide sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. The promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers. Accordingly, an "enhancer" is a nucleotide sequence which can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a promoter. Promoters may be derived in their entirety from a native gene, or may be composed of different elements derived from different promoters found in nature, or may even comprise synthetic nucleotide segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. Promoters which cause a nucleic acid fragment to be expressed in most cell types at most times are commonly referred to as "constitutive promoters". New promoters of

various types useful in plant cells are constantly being discovered; numerous examples may be found in the compilation by Okamuro and Goldberg (1989) *Biochemistry of Plants* 15:1-82. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, nucleic acid fragments of different lengths may have identical promoter activity.

5 [0049] "Translation leader sequence" refers to a nucleotide sequence located between the promoter sequence of a gene and the coding sequence. The translation leader sequence is present in the fully processed mRNA upstream of the translation Start sequence. The translation leader sequence may affect processing of the primary transcript to mRNA, mRNA stability or translation efficiency. Examples of translation leader sequences have been described (Turner and Foster (1995) *Mol. Biotechnol.* 3:225-236).

10 [0050] "3' Non-coding sequences" refers to nucleotide sequences located downstream of a coding sequence and includes polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The use of different 3' non-coding sequences is exemplified by Ingelbrecht et al. (1989) *Plant Cell* 1:671-680.

15 [0051] "RNA transcript" refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from posttranscriptional processing of the primary transcript and is referred to as the mature RNA. "Messenger RNA (mRNA)" refers to the RNA that is without introns and can be translated into polypeptides by the cell. "cDNA" refers to DNA that is complementary to and derived from an mRNA template.

20 The cDNA can be single-stranded or converted to double stranded form using, for example, the Klenow fragment of DNA polymerase I. "Sense RNA" refers to an RNA transcript that includes the mRNA and can be translated into a polypeptide by the cell. "Antisense RNA" refers to an RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene (see U.S. Patent No. 5,107,065, incorporated herein by reference). The complementarity of an antisense RNA may be with any part of the specific nucleotide sequence, i.e., at the 5' non-coding sequence, 3' non-coding sequence, introns, or the coding sequence. "Functional RNA" refers to sense RNA, antisense RNA, ribozyme RNA, or other RNA that may not be translated but yet has an effect on cellular processes.

25 [0052] The term "operably linked" refers to the association of two or more nucleic acid fragments so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.

30 [0053] The term "expression", as used herein, refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid fragment of the invention. "Expression" may also refer to translation of mRNA into a polypeptide. "Antisense inhibition" refers to the production of antisense RNA transcripts capable of suppressing the expression of the target protein. "Overexpression" refers to the production of a gene product in transgenic organisms that exceeds levels of production in normal or non-transformed organisms. "Co-suppression" refers to the production of sense RNA transcripts capable of suppressing the expression of identical or substantially similar foreign or endogenous genes (U.S. Patent No. 5,231,020, incorporated herein by reference).

35 [0054] A "protein" or "polypeptide" is a chain of amino acids arranged in a specific order determined by the coding sequence in a polynucleotide encoding the polypeptide. Each protein or polypeptide has a unique function.

40 [0055] "Altered levels" or "altered expression" refer to the production of gene product(s) in transgenic organisms in amounts or proportions that differ from that of normal or non-transformed organisms.

45 [0056] "Null mutant" refers to a host cell which either lacks the expression of a certain polypeptide or expresses a polypeptide which is inactive or does not have any detectable expected enzymatic function.

50 [0057] "Mature protein" or the term "mature" when used in describing a protein refers to a post-translationally processed polypeptide; i.e., one from which any pre- or propeptides present in the primary translation product have been removed. "Precursor protein" or the term "precursor" when used in describing a protein refers to the primary product of translation of mRNA; i.e., with pre- and propeptides still present. Pre- and propeptides may be but are not limited to intracellular localization signals.

55 [0058] A "chloroplast transit peptide" is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the chloroplast or other plastid types present in the cell in which the protein is made. "Chloroplast transit sequence" refers to a nucleotide sequence that encodes a chloroplast transit peptide. A "signal peptide" is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the secretory system (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53). If the protein is to be directed to a vacuole, a vacuolar targeting signal (*supra*) can further be added, or if to the endoplasmic reticulum, an endoplasmic reticulum retention signal (*supra*) may be added. If the protein is to be directed to the nucleus, any signal peptide present should be removed and instead a nuclear localization signal included (Raikhel (1992) *Plant Phys.* 100:1627-1632).

[0059] "Transformation" refers to the transfer of a nucleic acid fragment into the genome of a host organism, resulting

in genetically stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as "transgenic" organisms. Examples of methods of plant transformation include *Agrobacterium-mediated* transformation (De Blaere et al. (1987) *Meth. Enzymol.* 143:277) and particle-accelerated or "gene gun" transformation technology (Klein et al. (1987) *Nature (London)* 327:70-73; U.S. Patent No. 4,945,050, incorporated herein by reference). Thus,

5 isolated polynucleotides of the present invention can be incorporated into recombinant constructs, typically DNA constructs, capable of introduction into and replication in a host cell. Such a construct can be a vector that includes a replication system and sequences that are capable of transcription and translation of a polypeptide-encoding sequence in a given host cell. A number of vectors suitable for stable transfection of plant cells or for the establishment of trans-

10 genic plants have been described in, e.g., Pouwels et al., *Cloning Vectors: A Laboratory Manual*, 1985, supp. 1987;

15 Weissbach and Weissbach, *Methods for Plant Molecular Biology*, Academic Press, 1989; and Flevin et al., *Plant Molecular Biology Manual*, Kluwer Academic Publishers, 1990. Typically, plant expression vectors include, for example, one or more cloned plant genes under the transcriptional control of 5' and 3' regulatory sequences and a dominant selectable marker. Such plant expression vectors also can contain a promoter regulatory region (e.g., a regulatory

15 region controlling inducible or constitutive, environmentally- or developmentally-regulated, or cell- or tissue-specific expression), a transcription initiation start site, a ribosome binding site, an RNA processing signal, a transcription termination site, and/or a polyadenylation signal.

[0060] Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described more fully in Sambrook et al. *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter "Maniatis").

20 [0061] "PCR" or "polymerase chain reaction" is well known by those skilled in the art as a technique used for the amplification of specific DNA segments (U.S. Patent Nos. 4,683,195 and 4,800,159).

[0062] The present invention concerns an isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) a first nucleotide sequence encoding a polypeptide of at least 560 amino acids having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group 25 consisting of SEQ ID NOs:2, 4, 8, and 10 or (b) a second nucleotide sequence comprising the complement of the first nucleotide sequence.

[0063] Preferably, the nucleotide sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 7, and 9, that codes for the polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 8, and 10.

30 [0064] Nucleic acid fragments encoding at least a substantial portion of several plastidic phosphoglucomutase proteins have been isolated and identified by comparison of random plant cDNA sequences to public databases containing nucleotide and protein sequences using the BLAST algorithms well known to those skilled in the art. The nucleic acid fragments of the instant invention may be used to isolate cDNAs and genes encoding homologous proteins from the same or other plant species. Isolation of homologous genes using sequence-dependent protocols is well known in the 35 art. Examples of sequence-dependent protocols include, but are not limited to, methods of nucleic acid hybridization, and methods of DNA and RNA amplification as exemplified by various uses of nucleic acid amplification technologies (e.g., polymerase chain reaction, ligase chain reaction).

[0065] For example, genes encoding other plastidic phosphoglucomutases, either as cDNAs or genomic DNAs, could be isolated directly by using all or a substantial portion of the instant nucleic acid fragments as DNA hybridization 40 probes to screen libraries from any desired plant employing methodology well known to those skilled in the art. Specific oligonucleotide probes based upon the instant nucleic acid sequences can be designed and synthesized by methods known in the art (Maniatis). Moreover, an entire sequence(s) can be used directly to synthesize DNA probes by methods known to the skilled artisan such as random primer DNA labeling, nick translation, end-labeling techniques, or RNA probes using available *in vitro* transcription systems. In addition, specific primers can be designed and used to amplify 45 a part or all of the instant sequences. The resulting amplification products can be labeled directly during amplification reactions or labeled after amplification reactions, and used as probes to isolate full length cDNA or genomic fragments under conditions of appropriate stringency.

[0066] In addition, two short segments of the instant nucleic acid fragments may be used in polymerase chain reaction 50 protocols to amplify longer nucleic acid fragments encoding homologous genes from DNA or RNA. The polymerase chain reaction may also be performed on a library of cloned nucleic acid fragments wherein the sequence of one primer is derived from the instant nucleic acid fragments, and the sequence of the other primer takes advantage of the presence of the polyadenylic acid tracts to the 3' end of the mRNA precursor encoding plant genes. Alternatively, the second primer sequence may be based upon sequences derived from the cloning vector. For example, the skilled artisan can follow the RACE protocol (Frohman et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:8998-9002) to generate cDNAs by 55 using PCR to amplify copies of the region between a single point in the transcript and the 3' or 5' end. Primers oriented in the 3' and 5' directions can be designed from the instant sequences. Using commercially available 3' RACE or 5' RACE systems (BRL), specific 3' or 5' cDNA fragments can be isolated (Ohara et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:5673-5677; Loh et al. (1989) *Science* 243:217-220). Products generated by the 3' and 5' RACE procedures can be

combined to generate full-length cDNAs (Frohman and Martin (1989) *Techniques* 1:165). Consequently, a polynucleotide comprising a nucleotide sequence of at least 30 contiguous nucleotides, preferably at least 40 contiguous nucleotides, most preferably at least 60 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, and 9, and the complement of such nucleotide sequences may be used in such methods to obtain a nucleic acid fragment encoding a substantial portion of an amino acid sequence of a polypeptide.

5 [0067] The present invention relates to a method of obtaining a nucleic acid fragment encoding a substantial portion of a plastidic phosphoglucomutase polypeptide, preferably a substantial portion of a plant plastidic phosphoglucomutase polypeptide, comprising the steps of: synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least 30 contiguous nucleotides, preferably at least 40 contiguous nucleotides, most preferably at least 60 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, and 9, and the complement of such nucleotide sequences; and amplifying a nucleic acid fragment (preferably a cDNA inserted in a cloning vector) using the oligonucleotide primer. The amplified nucleic acid fragment preferably will encode a substantial portion of a plastidic phosphoglucomutase polypeptide.

10 [0068] Availability of the instant nucleotide and deduced amino acid sequences facilitates immunological screening of cDNA expression libraries. Synthetic peptides representing substantial portions of the instant amino acid sequences may be synthesized. These peptides can be used to immunize animals to produce polyclonal or monoclonal antibodies with specificity for peptides or proteins comprising the amino acid sequences. These antibodies can be then be used to screen cDNA expression libraries to isolate full-length cDNA clones of interest (Lerner (1984) *Adv. Immunol.* 36: 15 1-34; Maniatis).

15 [0069] In another embodiment, this invention concerns viruses and host cells comprising either the chimeric genes of the invention as described herein or an isolated polynucleotide of the invention as described herein. Examples of host cells which can be used to practice the invention include, but are not limited to, yeast, bacteria, and plants.

20 [0070] As was noted above, the nucleic acid fragments of the instant invention may be used to create transgenic plants in which the disclosed polypeptides are present at higher or lower levels than normal or in cell types or developmental stages in which they are not normally found. This would have the effect of altering the level of starch and soluble carbohydrate biosynthesis in those cells.

25 [0071] Overexpression of the proteins of the instant invention may be accomplished by first constructing a chimeric gene in which the coding region is operably linked to a promoter capable of directing expression of a gene in the desired tissues at the desired stage of development. The chimeric gene may comprise promoter sequences and translation leader sequences derived from the same genes. 3' Non-coding sequences encoding transcription termination signals may also be provided. The instant chimeric gene may also comprise one or more introns in order to facilitate gene expression.

30 [0072] Plasmid vectors comprising the instant isolated polynucleotide (or chimeric gene) may be constructed. The choice of plasmid vector is dependent upon the method that will be used to transform host plants. The skilled artisan is well aware of the genetic elements that must be present on the plasmid vector in order to successfully transform, select and propagate host cells containing the chimeric gene. The skilled artisan will also recognize that different independent transformation events will result in different levels and patterns of expression (Jones et al. (1985) *EMBO J.* 4:2411-2418; De Almeida et al. (1989) *Mol. Gen. Genetics* 218:78-86), and thus that multiple events must be screened 35 in order to obtain lines displaying the desired expression level and pattern. Such screening may be accomplished by Southern analysis of DNA, Northern analysis of mRNA expression, Western analysis of protein expression, or phenotypic analysis.

40 [0073] For some applications it may be useful to direct the instant polypeptides to different cellular compartments, or to facilitate secretion from the cell. It is thus envisioned that the chimeric gene described above may be further 45 supplemented by directing the coding sequence to encode the instant polypeptides with appropriate intracellular targeting sequences such as transit sequences (Keegstra (1989) *Cell* 56:247-253), signal sequences or sequences encoding endoplasmic reticulum localization (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53), or nuclear localization signals (Raikhel (1992) *Plant Phys.* 100:1627-1632) with or without removing targeting sequences that are already present. While the references cited give examples of each of these, the list is not exhaustive and more 50 targeting signals of use may be discovered in the future.

55 [0074] It may also be desirable to reduce or eliminate expression of genes encoding the instant polypeptides in plants for some applications. In order to accomplish this, a chimeric gene designed for co-suppression of the instant polypeptide can be constructed by linking a gene or gene fragment encoding that polypeptide to plant promoter sequences. Alternatively, a chimeric gene designed to express antisense RNA for all or part of the instant nucleic acid fragment can be constructed by linking the gene or gene fragment in reverse orientation to plant promoter sequences. Either the co-suppression or antisense chimeric genes could be introduced into plants via transformation wherein expression of the corresponding endogenous genes are reduced or eliminated.

60 [0075] Molecular genetic solutions to the generation of plants with altered gene expression have a decided advantage

over more traditional plant breeding approaches. Changes in plant phenotypes can be produced by specifically inhibiting expression of one or more genes by antisense inhibition or cosuppression (U.S. Patent Nos. 5,190,931, 5,107,065 and 5,283,323). An antisense or cosuppression construct would act as a dominant negative regulator of gene activity. While conventional mutations can yield negative regulation of gene activity these effects are most likely recessive. The dominant negative regulation available with a transgenic approach may be advantageous from a breeding perspective. In addition, the ability to restrict the expression of a specific phenotype to the reproductive tissues of the plant by the use of tissue specific promoters may confer agronomic advantages relative to conventional mutations which may have an effect in all tissues in which a mutant gene is ordinarily expressed.

[0076] The person skilled in the art will know that special considerations are associated with the use of antisense or cosuppression technologies in order to reduce expression of particular genes. For example, the proper level of expression of sense or antisense genes may require the use of different chimeric genes utilizing different regulatory elements known to the skilled artisan. Once transgenic plants are obtained by one of the methods described above, it will be necessary to screen individual transgenics for those that most effectively display the desired phenotype. Accordingly, the skilled artisan will develop methods for screening large numbers of transformants. The nature of these screens will generally be chosen on practical grounds. For example, one can screen by looking for changes in gene expression by using antibodies specific for the protein encoded by the gene being suppressed, or one could establish assays that specifically measure enzyme activity. A preferred method will be one which allows large numbers of samples to be processed rapidly, since it will be expected that a large number of transformants will be negative for the desired phenotype.

[0077] In another embodiment, the present invention concerns a polypeptide of at least 560 amino acids that has at least 95% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 8 and 10.

[0078] The instant polypeptides (or substantial portions thereof) may be produced in heterologous host cells, particularly in the cells of microbial hosts, and can be used to prepare antibodies to these proteins by methods well known to those skilled in the art. The antibodies are useful for detecting the polypeptides of the instant invention *in situ* in cells or *in vitro* in cell extracts. Preferred heterologous host cells for production of the instant polypeptides are microbial hosts. Microbial expression systems and expression vectors containing regulatory sequences that direct high level expression of foreign proteins are well known to those skilled in the art. Any of these could be used to construct a chimeric gene for production of the instant polypeptides. This chimeric gene could then be introduced into appropriate microorganisms via transformation to provide high level expression of the encoded plastidic phosphoglucomutase protein. An example of a vector for high level expression of the instant polypeptides in a bacterial host is provided (Example 6).

[0079] All or a substantial portion of the polynucleotides of the instant invention may also be used as probes for genetically and physically mapping the genes that they are a part of, and used as markers for traits linked to those genes. Such information may be useful in plant breeding in order to develop lines with desired phenotypes. For example, the instant nucleic acid fragments may be used as restriction fragment length polymorphism (RFLP) markers. Southern blots (Maniatis) of restriction-digested plant genomic DNA may be probed with the nucleic acid fragments of the instant invention. The resulting banding patterns may then be subjected to genetic analyses using computer programs such as MapMaker (Lander et al. (1987) *Genomics* 1:174-181) in order to construct a genetic map. In addition, the nucleic acid fragments of the instant invention may be used to probe Southern blots containing restriction endonuclease-treated genomic DNAs of a set of individuals representing parent and progeny of a defined genetic cross. Segregation of the DNA polymorphisms is noted and used to calculate the position of the instant nucleic acid sequence in the genetic map previously obtained using this population (Botstein et al. (1980) *Am. J. Hum. Genet.* 32:314-331).

[0080] The production and use of plant gene-derived probes for use in genetic mapping is described in Bernatzky and Tanksley (1986) *Plant Mol. Biol. Reporter* 4:37-41. Numerous publications describe genetic mapping of specific cDNA clones using the methodology outlined above or variations thereof. For example, F2 intercross populations, backcross populations, randomly mated populations, near isogenic lines, and other sets of individuals may be used for mapping. Such methodologies are well known to those skilled in the art.

[0081] Nucleic acid probes derived from the instant nucleic acid sequences may also be used for physical mapping (i.e., placement of sequences on physical maps; see Hoheisel et al. In: *Nonmammalian Genomic Analysis: A Practical Guide*, Academic press 1996, pp. 319-346, and references cited therein).

[0082] In another embodiment, nucleic acid probes derived from the instant nucleic acid sequences may be used in direct fluorescence *in situ* hybridization (FISH) mapping (Trask (1991) *Trends Genet.* 7:149-154). Although current methods of FISH mapping favor use of large clones (several to several hundred KB; see Laan et al. (1995) *Genome Res.* 5:13-20), improvements in sensitivity may allow performance of FISH mapping using shorter probes.

[0083] A variety of nucleic acid amplification-based methods of genetic and physical mapping may be carried out using the instant nucleic acid sequences. Examples include allele-specific amplification (Kazazian (1989) *J. Lab. Clin. Med.* 11:95-96), polymorphism of PCR-amplified fragments (CAPS; Sheffield et al. (1993) *Genomics* 16:325-332),

allele-specific ligation (Landegren et al. (1988) *Science* 241:1077-1080), nucleotide extension reactions (Sokolov (1990) *Nucleic Acid Res.* 18:3671), Radiation Hybrid Mapping (Walter et al. (1997) *Nat. Genet.* 7:22-28) and Happy Mapping (Dear and Cook (1989) *Nucleic Acid Res.* 17:6795-6807). For these methods, the sequence of a nucleic acid fragment is used to design and produce primer pairs for use in the amplification reaction or in primer extension reactions.

5 The design of such primers is well known to those skilled in the art. In methods employing PCR-based genetic mapping, it may be necessary to identify DNA sequence differences between the parents of the mapping cross in the region corresponding to the instant nucleic acid sequence. This, however, is generally not necessary for mapping methods. [0084] Loss of function mutant phenotypes may be identified for the instant cDNA clones either by targeted gene disruption protocols or by identifying specific mutants for these genes contained in a maize population carrying mutations in all possible genes (Ballinger and Benzer (1989) *Proc. Natl. Acad. Sci USA* 86:9402-9406; Koes et al. (1995) *Proc. Natl. Acad. Sci USA* 92:8149-8153; Bensen et al. (1995) *Plant Cell* 7:75-84). The latter approach may be accomplished in two ways. First, short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols in conjunction with a mutation tag sequence primer on DNAs prepared from a population of plants in which Mutator transposons or some other mutation-causing DNA element has been introduced (see Bensen, *supra*). 10 15 20

The amplification of a specific DNA fragment with these primers indicates the insertion of the mutation tag element in or near the plant gene encoding the instant polypeptides. Alternatively, the instant nucleic acid fragment may be used as a hybridization probe against PCR amplification products generated from the mutation population using the mutation tag sequence primer in conjunction with an arbitrary genomic site primer, such as that for a restriction enzyme site-anchored synthetic adaptor. With either method, a plant containing a mutation in the endogenous gene encoding the instant polypeptides can be identified and obtained. This mutant plant can then be used to determine or confirm the natural function of the instant polypeptides disclosed herein.

EXAMPLES

25 [0085] The present invention is further defined in the following Examples, in which parts and percentages are by weight and degrees are Celsius, unless otherwise stated. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages 30 and conditions. Thus, various modifications of the invention in addition to those shown and described herein will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

[0086] The disclosure of each reference set forth herein is incorporated herein by reference in its entirety.

35 EXAMPLE 1

Composition of cDNA Libraries; Isolation and Sequencing of cDNA Clones

40 [0087] cDNA libraries representing mRNAs from various cattail, corn, rice and soybean tissues were prepared. The characteristics of the libraries are described below.

TABLE 2

cDNA Libraries from Cattail, Corn, Rice and Soybean		
Library	Tissue	Clone
etr1c	Cattail (<i>Typha latifolia</i>) root	etr1c.pk005.f8
p0075	Corn, root/leaf material from dark-grown 7 day old Seedlings	p0075.cs1af22f p0075.cs1af22rb
p0128	Corn, pooled primary and secondary immature ear	p0128.cpicz81r
rdi1c	Rice (<i>Oryza sativa</i> , <i>Nipponbare</i>) developing inflorescence at mitotic stage	rdi1c.pk001.a22
rth1c	Rice leaf inoculated with <i>Magnaporthe grisea</i>	rth1c.pk009.k14f
sdp3c	Soybean developing pods 8-9 mm	sdp3c.pk003.e22

55 [0088] cDNA libraries may be prepared by any one of many methods available. For example, the cDNAs may be introduced into plasmid vectors by first preparing the cDNA libraries in Uni-ZAP™ XR vectors according to the manufacturer's protocol (Stratagene Cloning Systems, La Jolla, CA). The Uni-ZAP™ XR libraries are converted into plasmid libraries according to the protocol provided by Stratagene. Upon conversion, cDNA inserts will be contained in the

5 plasmid vector pBluescript. In addition, the cDNAs may be introduced directly into precut Bluescript II SK(+) vectors (Stratagene) using T4 DNA ligase (New England Biolabs), followed by transfection into DH10B cells according to the manufacturer's protocol (GIBCO BRL Products). Once the cDNA inserts are in plasmid vectors, plasmid DNAs are prepared from randomly picked bacterial colonies containing recombinant pBluescript plasmids, or the insert cDNA sequences are amplified via polymerase chain reaction using primers specific for vector sequences flanking the inserted cDNA sequences. Amplified insert DNAs or plasmid DNAs are sequenced in dye-primer sequencing reactions to generate partial cDNA sequences (expressed sequence tags or "ESTs"; see Adams et al., (1991) *Science* 252:1651-1656). The resulting ESTs are analyzed using a Perkin Elmer Model 377 fluorescent sequencer.

10 EXAMPLE 2Identification of cDNA Clones

15 [0089] cDNA clones encoding plastidic phosphoglucomutase proteins were identified by conducting BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also www.ncbi.nlm.nih.gov/BLAST/) searches for similarity to sequences contained in the BLAST "nr" database (comprising all non-redundant GenBank CDS translations, sequences derived from the 3-dimensional structure Brookhaven Protein Data Bank, the last major release of the SWISS-PROT protein sequence database, EMBL, and DDBJ databases). The cDNA sequences obtained in Example 1 were analyzed for similarity to all publicly available DNA sequences contained in the "nr" database 20 using the BLASTN algorithm provided by the National Center for Biotechnology Information (NCBI). The DNA sequences were translated in all reading frames and compared for similarity to all publicly available protein sequences contained in the "nr" database using the BLASTX algorithm (Gish and States (1993) *Nat. Genet.* 3:266-272) provided by the NCBI. For convenience, the P-value (probability) of observing a match of a cDNA sequence to a sequence contained 25 in the searched databases merely by chance as calculated by BLAST are reported herein as "pLog" values, which represent the negative of the logarithm of the reported P-value. Accordingly, the greater the pLog value, the greater the likelihood that the cDNA sequence and the BLAST "hit" represent homologous proteins.

EXAMPLE 330 Characterization of cDNA Clones Encoding Plastidic Phosphoglucomutase Proteins

35 [0090] The BLASTX search using the EST sequences from clones listed in Table 3 revealed similarity of the polypeptides encoded by the cDNAs to plastidic phosphoglucomutase from *Brassica napus* (NCBI Identifier No. gi 6272125) and *Pisum sativum* (NCBI Identifier No. gi 6272283 and NCBI Identifier No. gi 10190529). Shown in Table 3 are the BLAST results for individual ESTs ("EST"), the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), contigs assembled from two or more ESTs ("Contig"), contigs assembled from an FIS and one or more ESTs ("Contig*"), or sequences encoding the entire protein derived from an FIS, a contig, an EST and PCR, or an FIS and PCR ("CGS");

40 TABLE 3

BLAST Results for Sequences Encoding Polypeptides Homologous to <i>Brassica napus</i> and <i>Pisum sativum</i> Plastidic Phosphoglucomutase			
	Clone	Status	BLAST pLog Score
45	etr1c.pk005.f8 (FIS)	CGS	>254.00 (gi 6272125; <i>B. napus</i>)
	Contig Composed of:	CGS	>254.00 (gi 6272283; <i>P. sativum</i>)
	p0075.cslaf22f (EST)		
	p0075.cslaf22rb (EST)		
	p0128.cpicz81r(EST)		
50	rth1c.pk009.k14f (EST)	EST	58.00 (gi 6272283; <i>P. sativum</i>)
	sdp3c.pk003.e22 (EST and PCR Fragments)	CGS	>254.00 (gi 6272283; <i>P. sativum</i>)
	rdi1c.pk001.a22 (FIS)	CGS	180.00 (gi 10190529; <i>P. sativum</i>)

55 [0091] The data in Table 4 represents a calculation of the percent identity of the amino acid sequences set forth in SEQ ID NOS:2, 4, 6, 8, and 10, and the *Brassica napus* and *Pisum sativum* sequences.

TABLE 4

Percent Identity of Amino Acid Sequences Deduced From the Nucleotide Sequences of cDNA Clones Encoding Polypeptides Homologous to <i>Brassica napus</i> and <i>Pisum sativum</i> Plastidic Phosphoglucomutase	
SEQ ID NO.	Percent Identity to
2	79% (gi 6272125; <i>B. napus</i>)
4	77% (gi 6272283; <i>P. sativum</i>)
6	80% (gi 6272283; <i>P. sativum</i>)
8	90% (gi 6272283; <i>P. sativum</i>)
10	76% (gi 10190529; <i>P. sativum</i>)

[0092] Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) CABIOS. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. Sequence alignments, BLAST scores and probabilities indicate that the nucleic acid fragments comprising the instant cDNA clones encode a substantial portion of a plastidic phosphoglucomutase.

EXAMPLE 4

Expression of Chimeric Genes in Monocot Cells

[0093] A chimeric gene comprising a cDNA encoding the instant polypeptides in sense orientation with respect to the maize 27 kD zein promoter that is located 5' to the cDNA fragment, and the 10 kD zein 3' end that is located 3' to the cDNA fragment, can be constructed. The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites (Ncol or SmaI) can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the digested vector pML103 as described below. Amplification is then performed in a standard PCR. The amplified DNA is then digested with restriction enzymes Ncol and SmaI and fractionated on an agarose gel. The appropriate band can be isolated from the gel and combined with a 4.9 kb Ncol-SmaI fragment of the plasmid pML103. Plasmid pML103 has been deposited under the terms of the Budapest Treaty at ATCC (American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209), and bears accession number ATCC 97366. The DNA segment from pML103 contains a 1.05 kb Sall-Ncol promoter fragment of the maize 27 kD zein gene and a 0.96 kb SmaI-Sall fragment from the 3' end of the maize 10 kD zein gene in the vector pGem9zf(+) (Promega). Vector and insert DNA can be ligated at 15°C overnight, essentially as described (Maniatis). The ligated DNA may then be used to transform *E. coli* XL1-Blue (Epicurian Coli XL-1 Blue™; Stratagene). Bacterial transformants can be screened by restriction enzyme digestion of plasmid DNA and limited nucleotide sequence analysis using the dideoxy chain termination method (Sequenase™ DNA Sequencing Kit; U.S. Biochemical). The resulting plasmid construct would comprise a chimeric gene encoding, in the 5' to 3' direction, the maize 27 kD zein promoter, a cDNA fragment encoding the instant polypeptides, and the 10 kD zein 3' region.

[0094] The chimeric gene described above can then be introduced into corn cells by the following procedure. Immature corn embryos can be dissected from developing caryopses derived from crosses of the inbred corn lines H99 and LH132. The embryos are isolated 10 to 11 days after pollination when they are 1.0 to 1.5 mm long. The embryos are then placed with the axis-side facing down and in contact with agarose-solidified N6 medium (Chu et al. (1975) *Sci. Sin. Peking* 18:659-668). The embryos are kept in the dark at 27°C. Friable embryogenic callus consisting of undifferentiated masses of cells with somatic proembryoids and embryos borne on suspensor structures proliferates from the scutellum of these immature embryos. The embryogenic callus isolated from the primary explant can be cultured on N6 medium and sub-cultured on this medium every 2 to 3 weeks.

[0095] The plasmid, p35S/Ac (obtained from Dr. Peter Eckes, Hoechst Ag, Frankfurt, Germany) may be used in transformation experiments in order to provide for a selectable marker. This plasmid contains the *Pat* gene (see European Patent Publication 0 242 236) which encodes phosphinothricin acetyl transferase (PAT). The enzyme PAT confers resistance to herbicidal glutamine synthetase inhibitors such as phosphinothricin. The *pat* gene in p35S/Ac is under the control of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*.

[0096] The particle bombardment method (Klein et al. (1987) *Nature* 327:70-73) may be used to transfer genes to

the callus culture cells. According to this method, gold particles (1 μ m in diameter) are coated with DNA using the following technique. Ten μ g of plasmid DNAs are added to 50 μ L of a suspension of gold particles (60 mg per mL). Calcium chloride (50 μ L of a 2.5 M solution) and spermidine free base (20 μ L of a 1.0 M solution) are added to the particles. The suspension is vortexed during the addition of these solutions. After 10 minutes, the tubes are briefly centrifuged (5 sec at 15,000 rpm) and the supernatant removed. The particles are resuspended in 200 μ L of absolute ethanol, centrifuged again and the supernatant removed. The ethanol rinse is performed again and the particles re-suspended in a final volume of 30 μ L of ethanol. An aliquot (5 μ L) of the DNA-coated gold particles can be placed in the center of a KaptonTM flying disc (Bio-Rad Labs). The particles are then accelerated into the corn tissue with a BiostaticTM PAS-1000/He (Bio-Rad Instruments, Hercules CA), using a helium pressure of 1000 psi, a gap distance of 0.5 cm and a flying distance of 1.0 cm.

[0097] For bombardment, the embryogenic tissue is placed on filter paper over agarose-solidified N6 medium. The tissue is arranged as a thin lawn and covered a circular area of about 5 cm in diameter. The petri dish containing the tissue can be placed in the chamber of the PDS-1000/He approximately 8 cm from the stopping screen. The air in the chamber is then evacuated to a vacuum of 28 inches of Hg. The macrocarrier is accelerated with a helium shock wave using a rupture membrane that bursts when the He pressure in the shock tube reaches 1000 psi.

[0098] Seven days after bombardment the tissue can be transferred to N6 medium that contains glufosinate (2 mg per liter) and lacks casein or proline. The tissue continues to grow slowly on this medium. After an additional 2 weeks the tissue can be transferred to fresh N6 medium containing glufosinate. After 6 weeks, areas of about 1 cm in diameter of actively growing callus can be identified on some of the plates containing the glufosinate-supplemented medium. These calli may continue to grow when sub-cultured on the selective medium.

[0099] Plants can be regenerated from the transgenic callus by first transferring clusters of tissue to N6 medium supplemented with 0.2 mg per liter of 2,4-D. After two weeks the tissue can be transferred to regeneration medium (Fromm et al. (1990) *Bio/Technology* 8:833-839).

EXAMPLE 5

Expression of Chimeric Genes in Dicot Cells

[0100] A seed-specific construct composed of the promoter and transcription terminator from the gene encoding the β subunit of the seed storage protein phaseolin from the bean *Phaseolus vulgaris* (Doyle et al. (1986) *J. Biol. Chem.* 261:9228-9238) can be used for expression of the instant polypeptides in transformed soybean. The phaseolin construct includes about 500 nucleotides upstream (5') from the translation initiation codon and about 1650 nucleotides downstream (3') from the translation stop codon of phaseolin. Between the 5' and 3' regions are the unique restriction endonuclease sites Nco I (which includes the ATG translation initiation codon), Sma I, Kpn I and Xba I. The entire construct is flanked by Hind III sites.

[0101] The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the expression vector. Amplification is then performed as described above, and the isolated fragment is inserted into a pUC18 vector carrying the seed construct.

[0102] Soybean embryos may then be transformed with the expression vector comprising sequences encoding the instant polypeptides. To induce somatic embryos, cotyledons, 3-5 mm in length dissected from surface sterilized, immature seeds of the soybean cultivar A2872, can be cultured in the light or dark at 26°C on an appropriate agar medium for 6-10 weeks. Somatic embryos which produce secondary embryos are then excised and placed into a suitable liquid medium. After repeated selection for clusters of somatic embryos which multiplied as early, globular staged embryos, the suspensions are maintained as described below.

[0103] Soybean embryogenic suspension cultures can be maintained in 35 mL of liquid media on a rotary shaker, 150 rpm, at 26°C with florescent lights on a 16:8 hour day/night schedule. Cultures are subcultured every two weeks by inoculating approximately 35 mg of tissue into 35 mL of liquid medium.

[0104] Soybean embryogenic suspension cultures may then be transformed by the method of particle gun bombardment (Klein et al. (1987) *Nature* (London) 327:70-73, U.S. Patent No. 4,945,050). A DuPont BiostaticTM PDS1000/HE instrument (helium retrofit) can be used for these transformations.

[0105] A selectable marker gene which can be used to facilitate soybean transformation is a chimeric gene composed of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812), the hygromycin phosphotransferase gene from plasmid pJR225 (from *E. coli*; Gritz et al. (1983) *Gene* 25:179-188) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*. The seed construct comprising the phaseolin 5' region, the fragment encoding the instant polypeptides and the phaseolin 3' region can be isolated as a restriction fragment. This fragment can then be inserted into a unique restriction site of the vector carrying the marker gene.

[0106] To 50 μ L of a 60 mg/mL 1 μ m gold particle suspension is added (in order): 5 μ L DNA (1 μ g/ μ L), 20 μ L spermidine (0.1 M), and 50 μ L CaCl₂ (2.5 M). The particle preparation is then agitated for three minutes, spun in a microfuge for 10 seconds and the supernatant removed. The DNA-coated particles are then washed once in 400 μ L 70% ethanol and resuspended in 40 μ L of anhydrous ethanol. The DNA/particle suspension can be sonicated three times for one second each. Five μ L of the DNA-coated gold particles are then loaded on each macro carrier disk.

[0107] Approximately 300-400 mg of a two-week-old suspension culture is placed in an empty 60x15 mm petri dish and the residual liquid removed from the tissue with a pipette. For each transformation experiment, approximately 5-10 plates of tissue are normally bombarded. Membrane rupture pressure is set at 1100 psi and the chamber is evacuated to a vacuum of 28 inches of mercury. The tissue is placed approximately 3.5 inches away from the retaining screen and bombarded three times. Following bombardment, the tissue can be divided in half and placed back into liquid and cultured as described above.

[0108] Five to seven days post bombardment, the liquid media may be exchanged with fresh media, and eleven to twelve days post bombardment with fresh media containing 50 mg/mL hygromycin. This selective media can be refreshed weekly. Seven to eight weeks post bombardment, green, transformed tissue may be observed growing from untransformed, necrotic, embryogenic clusters. Isolated green tissue is removed and inoculated into individual flasks to generate new, clonally propagated, transformed embryogenic suspension cultures. Each new line may be treated as an independent transformation event. These suspensions can then be subcultured and maintained as clusters of immature embryos or regenerated into whole plants by maturation and germination of individual somatic embryos.

EXAMPLE 6

Expression of Chimeric Genes in Microbial Cells

[0109] The cDNAs encoding the instant polypeptides can be inserted into the T7 *E. coli* expression vector pBT430. This vector is a derivative of pET-3a (Rosenberg et al. (1987) *Gene* 56:125-135) which employs the bacteriophage T7 RNA polymerase/T7 promoter system. Plasmid pBT430 was constructed by first destroying the EcoR I and Hind III sites in pET-3a at their original positions. An oligonucleotide adaptor containing EcoR I and Hind III sites was inserted at the BamH I site of pET-3a. This created pET-3aM with additional unique cloning sites for insertion of genes into the expression vector. Then, the Nde I site at the position of translation initiation was converted to an Nco I site using oligonucleotide-directed mutagenesis. The DNA sequence of pET-3aM in this region, 5'-CATATGG, was converted to 5'-CCCATGG in pBT430.

[0110] Plasmid DNA containing a cDNA may be appropriately digested to release a nucleic acid fragment encoding the protein. This fragment may then be purified on a 1% NuSieve GTG™ low melting agarose gel (FMC). Buffer and agarose contain 10 μ g/mL ethidium bromide for visualization of the DNA fragment. The fragment can then be purified from the agarose gel by digestion with GELase™ (Epicentre Technologies) according to the manufacturer's instructions, ethanol precipitated, dried and resuspended in 20 μ L of water. Appropriate oligonucleotide adapters may be ligated to the fragment using T4 DNA ligase (New England Biolabs, Beverly, MA). The fragment containing the ligated adapters can be purified from the excess adapters using low melting agarose as described above. The vector pBT430 is digested, dephosphorylated with alkaline phosphatase (NEB) and deproteinized with phenol/chloroform as described above. The prepared vector pBT430 and fragment can then be ligated at 16°C for 15 hours followed by transformation into DH5 electrocompetent cells (GIBCO BRL). Transformants can be selected on agar plates containing LB media and 100 μ g/mL ampicillin. Transformants containing the gene encoding the instant polypeptides are then screened for the correct orientation with respect to the T7 promoter by restriction enzyme analysis.

[0111] For high level expression, a plasmid clone with the cDNA insert in the correct orientation relative to the T7 promoter can be transformed into *E. coli* strain BL21(DE3) (Studier et al. (1986) *J. Mol. Biol.* 189:113-130). Cultures are grown in LB medium containing ampicillin (100 mg/L) at 25°C. At an optical density at 600 nm of approximately 1, IPTG (isopropylthio- β -galactoside, the inducer) can be added to a final concentration of 0.4 mM and incubation can be continued for 3 h at 25°C. Cells are then harvested by centrifugation and re-suspended in 50 μ L of 50 mM Tris-HCl at pH 8.0 containing 0.1 mM DTT and 0.2 mM phenyl methylsulfonyl fluoride. A small amount of 1 mm glass beads can be added and the mixture sonicated 3 times for about 5 seconds each time with a microprobe sonicator. The mixture is centrifuged and the protein concentration of the supernatant determined. One μ g of protein from the soluble fraction of the culture can be separated by SDS-polyacrylamide gel electrophoresis. Gels can be observed for protein bands migrating at the expected molecular weight.

EXAMPLE 7**Transformation of Somatic Soybean Embryo Cultures****5 Generic stable soybean transformation protocol:**

[0112] Soybean embryogenic suspension cultures are maintained in 35 ml liquid media (SB55 or SBP6) on a rotary shaker, 150 rpm, at 28°C with mixed fluorescent and incandescent lights on a 16:8 h day/night schedule. Cultures are subcultured every four weeks by inoculating approximately 35 mg of tissue into 35 ml of liquid medium.

10

TABLE 1

Stock Solutions (g/L):		SB55 (per Liter, pH 5.7)
<u>MS Sulfate 100X Stock</u>		10 ml each MS stocks
MgSO ₄ 7H ₂ O	37.0	1 ml B5 Vitamin stock
MnSO ₄ H ₂ O	1.69	0.8 g NH ₄ NO ₃
ZnSO ₄ 7H ₂ O	0.86	3.033 g KNO ₃
CuSO ₄ 5H ₂ O	0.0025	1 ml 2,4-D (10mg/mL stock)
<u>MS Halides 100x stock</u>		60 g sucrose
CaCl ₂ 2H ₂ O	44.0	0.667 g asparagine
KI	0.083	
CoCl ₂ 6H ₂ O	0.00125	SBP6
KH ₂ PO ₄	17.0	same as SB55 except 0.5 ml 2,4-D
H ₃ BO ₃	0.62	
Na ₂ MoO ₄ 2H ₂ O	0.025	SB103 (per Liter, pH 5.7)
<u>MS FeEDTA 100X Stock</u>		1X MS Salts
Na ₂ EDTA	3.724	6% maltose
FeSO ₄ 7H ₂ O	2.784	750 mg MgCl ₂
<u>B5 Vitamin Stock</u>		0.2% Gelrite
10 g m-inositol		SB71-1 (per Liter, pH 5.7)
100 mg nicotinic acid		1X B5 salts
100 mg pyridoxine HCl		1 ml B5 vitamin stock
1 g thiamine		3% sucrose
		750 mg MgCl ₂
		0.2% Gelrite

35

[0113] Soybean embryogenic suspension cultures are transformed with plasmid DNA by the method of particle gun bombardment (Klein et al (1987) *Nature* 327:70). A DuPont Biolistic PDS1000/HE instrument (helium retrofit) is used for these transformations.

40

[0114] To 50 ml of a 60 mg/ml 1 μ m gold particle suspension is added (in order): 5 μ l DNA(1 μ g/ μ l), 20 μ l spermidine (0.1 M), and 50 μ l CaCl₂ (2.5 M). The particle preparation is agitated for 3 min, spun in a microfuge for 10 sec and the supernatant removed. The DNA-coated particles are then washed once in 400 μ l 70% ethanol and re suspended in 40 μ l of anhydrous ethanol. The DNA/particle suspension is sonicated three times for 1 sec each. Five μ l of the DNA-coated gold particles are then loaded on each macro carrier disk. For selection, a plasmid conferring resistance to hygromycin phosphotransferase (HPT) may be co-bombarded with the silencing construct of interest.

45

[0115] Approximately 300-400 mg of a four week old suspension culture is placed in an empty 60x15 mm petri dish and the residual liquid removed from the tissue with a pipette. For each transformation experiment, approximately 5-10 plates of tissue are normally bombarded. Membrane rupture pressure is set at 1000 psi and the chamber is evacuated to a vacuum of 28 inches of mercury. The tissue is placed approximately 3.5 inches away from the retaining screen and bombarded three times. Following bombardment, the tissue is placed back into liquid and cultured as described above.

50

[0116] Eleven days post bombardment, the liquid media is exchanged with fresh SB55 containing 50 mg/ml hygromycin. The selective media is refreshed weekly. Seven weeks post bombardment, green, transformed tissue is observed growing from untransformed, necrotic embryogenic clusters. Isolated green tissue is removed and inoculated into individual flasks to generate new, clonally propagated, transformed embryogenic suspension cultures. Thus each new line is treated as an independent transformation event. These suspensions can then be maintained as suspensions of embryos maintained in an immature developmental stage or regenerated into whole plants by maturation and germination of individual somatic embryos.

[0117] Independent lines of transformed embryogenic clusters are removed from liquid culture and placed on a solid agar media (SB 103) containing no hormones or antibiotics. Embryos are cultured for four weeks at 26°C with mixed fluorescent and incandescent lights on a 16:8 h day/night schedule. During this period, individual embryos are removed from the clusters and screened for alterations in gene expression.

5 [0118] It should be noted that any detectable phenotype, resulting from the co-suppression of a target gene, can be screened at this stage. This would include, but not be limited to, alterations in protein content, carbohydrate content, growth rate, viability, or the ability to develop normally into a soybean plant.

EXAMPLE 8

10 **Plasmid DNAs for "Complementary Region" Co-suppression**

[0119] The plasmids used in these experiments were made using standard cloning methods well known to those skilled in the art (Sambrook et al (1989) *Molecular Cloning*, CSHL Press, New York). A starting plasmid pKS18HH (U. 15 S. Patent No. 5,846,784 the contents of which are hereby incorporated by reference) contains a hygromycin B phosphotransferase (HPT) obtained from *E. coli* strain W677 under the control of a T7 promoter and the 35S cauliflower mosaic virus promoter. Plasmid pKS 18HH thus contains the T7 promoter/HPT/17 terminator cassette for expression of the HPT enzyme in certain strains of *E. coli*, such as NovaBlue(DE3) [from Novagen], that are lysogenic for lambda DE3 (which carries the T7 RNA Polymerase gene under lacV5 control). Plasmid pKS18HH also contains the 35S/HPT/ 20 NOS cassette for constitutive expression of the HPT enzyme in plants, such as soybean. These two expression systems allow selection for growth in the presence of hygromycin to be used as a means of identifying cells that contain the plasmid in both bacterial and plant systems. pKS18HH also contains three unique restriction endonuclease sites suitable for the cloning other chimeric genes into this vector. Plasmid ZBL100 (PCT Application No. WO 00/11176 published on March 2, 2000) is a derivative of pKS18HH with a reduced NOS 3' terminator: Plasmid pKS67 is a ZBL100 derivative 25 with the insertion of a beta-conglycinin promoter, in front of a NotI cloning site, followed by a phaseolin 3' terminator (described in PCT Application No. WO 94/11516, published on May 26, 1994).

[0120] The 2.5 kb plasmid pKS 17 contains pSP72 (obtained from Promega Biosystems) and the T7 promoter/HPT/ T7 3' terminator region, and is the original vector into which the 3.2 kb BamHI-Sall fragment containing the 35S/HPT/ NOS cassette was cloned to form pKS18HH. The plasmid pKS102 is a pKS 17 derivative that is digested with XbaI 30 and Sall, treated with mung-bean nuclease to generate blunt ends, and ligated to insert the following linker:

GGCGCGCCAAGCTTGGATCCGTCACGGCGCGCC Artificial DNA No. 1

35 [0121] The plasmid pKS83 has the 2.3 kb BamHI fragment of ML70 containing the Kti3 promoter/NotI/Kti3 3' terminator region (described in PCT Application No. WO 94/11516, published on May 26, 1994) ligated into the BamHI site of pKS17.

40 **EXAMPLE 9**

Suppression by ELVISLIVES Complementary Region

[0122] Constructs have now been made which have "synthetic complementary regions" (SCR). In this example the 45 target sequence is placed between complementary sequences that are not known to be part of any biologically derived gene or genome (i.e. sequences that are "synthetic" or conjured up from the mind of the inventor). The target DNA would therefore be in the sense or antisense orientation and the complementary RNA would be unrelated to any known nucleic acid sequence. It is possible to design a standard "suppression vector" into which pieces of any target gene for suppression could be dropped. The plasmids pKS106, pKS124, and pKS133 (SEQ ID NO:17) exemplify this. One 50 skilled in the art will appreciate that all of the plasmid vectors contain antibiotic selection genes such as, but not limited to, hygromycin phosphotransferase with promoters such as the T7 inducible promoter.

[0123] pKS106 uses the beta-conglycinin promoter while the pKS124 and pKS133 plasmids use the Kti promoter, both of these promoters exhibit strong tissue specific expression in the seeds of soybean. pKS 106 uses a 3' termination region from the phaseolin gene, and pKS 124 and pKS133 use a Kti 3' termination region, pKS106 and pKS124 have 55 single copies of the 36 nucleotide EagI-ELVISLIVES sequence surrounding a NotI site (the amino acids given in parentheses are back-translated from the complementary strand): Artificial DNA No. 2

EagI E L V I S L I V E S NotI
CGGCCG GAG CTG GTC ATC TCG CTC ATC GTC GAG TCG
GCGGGCCGC

(S) (E) (V) (I) (L) (S) (I) (V) (L) (E) EagI

10 CGA CTC GAC GAT GAG CGA GAT GAC CAG CTC CGGCCG

pKS133 has 2X copies of ELVISLIVES surrounding the NotI site: Artificial DNA No. 3

15 EagI E L V I S L I V E S EagI E L V I S
ccggccggaaacctggatctcgatcatcgatcgaaatcg acggcccg aacctggatctcg

22 L I V E S Note (S) (E) (A) (I) (L) (S) (F) (V) (L) (E) (E)

EagI

ctcatcgtcagtcg cgccgcgc cgactcgacgatgagcgagatgaccagctc
cgccgc

25 (S) (E) (V) (I) (L) (S) (I) (V) (L) (E) EagI
cgactcgacgatgagcggatgaccaggctc cggccg

30 [0124] The idea is that the single EL linker (SCR) can be duplicated to increase stem lengths in increments of approximately 40 nucleotides. A series of vectors will cover the SCR lengths between 40 bp and the 300 bp. Various target gene lengths are also under evaluation, It is believed that certain combinations of target lengths and complementary region lengths will give optimum suppression of the target, although preliminary results would indicate that the suppression phenomenon works well over a wide range of sizes and sequences. It is also believed that the lengths and ratios providing optimum suppression may vary somewhat given different target sequences and/or complementary regions.

35

[0125] The plasmid pKS106 is made by putting the EagI fragment of ELVISLIVES (Artificial DNA No. 2) into the NotI site of pKS67. The ELVISLIVES fragment is made by PCR using two primers and no other DNA:

40

Artificial DNA No. 4
5'-GAATTCCGGCCGGAGCTGGTCATCTCGCTCATCGTCGAGTCGGCGGCCGCC
GACTGGACCGATGACGGAGATGACCGACGCTGGCGGCCGAAATTG-3'

Artificial DNA No. 5

5'-GAATTCCGGCCGGAG-3'

[0126] The product of the PCR reaction is digested with EagI (5'-CGGGCG-3') and then ligated into NotI digested pKS67. The term "ELVISLIVES" and "EL" are used interchangeably herein.

55 [0127] Additional plasmids can be used to test this example. For example, pKS121 contains the KtI3 promoter/NotI/KtI3 3' terminator fragment analogous to pKS83 inserted into the BamHI-Sall digested pKS 102. The EagI digested ELVISLIVES cloning site made from SEQ ID NOS:14 and 15 is inserted into the Nod site of pKS 121 to form pKS124. The EagI digested EL PCR product can be ligated into Nod digested pKS 124 to form the 2XEL plasmid, pKS133 (SEQ

EP 1 174 510 A2

5 ID NO:17), containing two copies of EL VISLIVES. An additional 2XEL vector, pKS 151, is similar to pKS133 except for the addition of a second hygromycin phosphotransferase gene with a 35S-CaMV promoter. Any synthetic sequence, or naturally occurring sequence, can be used in an analogous manner. The addition of a 574 base pair NotI fragment (SEQ ID NO: 14) into a NotI-digested pKS133 produces pTC103. The 574 base pair Not I fragment (SEQ ID NO:14) contains a 541 base pair region (SEQ ID NO:15) of the soybean plastid phosphoglucomutase coding region (SEQ ID NO:8).

EXAMPLE 10

10 Down Regulation of Plastidic Phosphoglucomutase in Soybean

15 [0128] Soybean was transformed with the plasmid DNA, pTC103, and transgenic lines were selected. Transgenic lines were screened for down regulation of plastidic phosphoglucomutase in soybean. The screening assay involved iodine staining for the presence or absence of starch in immature seeds (mid-pod stage). The method involved harvesting half of the seed, and putting that seed on dry ice and storing at -80C. The other half of the seed was placed in 100% ethanol overnight, and subsequently stained with water:lugol (4:1) solution for 10 to 30 minutes at room temperature. Lugol is an iodine/potassium iodide solution, commercially available from Sigma.

20 [0129] Four out of nineteen events showed a clear reduction in iodine staining indicating a reduction in starch content. This may reflect a 21% cosuppression success with the hairpin construct. Three additional events showed potential reduction in iodine staining, although the differences in staining were subtle. The segregation patterns of events 100-2-1 and 108-3-1 are consistent with a theoretical segregation of a dominant co-suppression (1:3).

TABLE 5:

Summary of Iodine Screen	
	<u>sum</u>
+ Events	4
- Events	12
? Events	3
Total Events Analyzed	19
Events with no plants/sterile/dwarf	2
Total Events	27

TABLE 6:

Seed segregation information of potential positive PGM events. D= dark blue stain, L= light blue or no stain, D/L in between dark and light stain			
Event	Plant	D:L seed ratio	Note
100-2-1	1	1:5	clear positive
	2	3:2	clear positive
	3	1:5	clear positive
108-3-1	1	0:6	clear positive
	2	2:4	clear positive
	3	1:5	clear positive
105-2-3	1	4:0	negative
	2	1:5	clear positive

TABLE 6: (continued)

Seed segregation information of potential positive PGM events. D= dark blue stain, L= light blue or no stain, D/L in between dark and light stain			
Event	Plant	D:L seed ratio	Note
105-1-6	1	4:0	negative
	3	2:2	clear positive
105-1-1	1	4:2	D/L
	2	0:6	D/L
	3	6:0	D/L
101-2-6	1	6:0	D/L
	3	2:3	D/L
102-3-3	1	2:3	D/L
	2	3:0	D/L

25 Claims

1. An isolated polynucleotide comprising:
 - (a) a first nucleotide sequence encoding a first polypeptide having phosphoglucomutase activity, wherein the amino acid sequence of the first polypeptide and the amino acid sequence of SEQ ID NO:8 have at least 95 % identity based on the Clustal alignment method,
 - (b) a second nucleotide sequence encoding a second polypeptide having phosphoglucomutase activity, wherein the amino acid sequence of the second polypeptide and the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:10 have at least 85% identity based on the Clustal alignment method, or
 - (c) the complement of the first or second nucleotide sequence.
2. The isolated polynucleotide of Claim 1 wherein the amino acid sequence of the second polypeptide and the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO: 10 have at least 90% identity based on the Clustal alignment method.
3. The isolated polynucleotide of Claim 1, wherein the amino acid sequence of the second polypeptide and the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:10 have at least 95% identity based on the Clustal alignment method.
4. The isolated polynucleotide of Claim 1, wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO:8, wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:10.
5. The isolated polynucleotide of Claim 1, wherein the first nucleotide sequence comprises the nucleotide sequence of SEQ ID NO:7, wherein the second nucleotide sequence comprises the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:9.
6. A chimeric gene comprising the polynucleotide of Claim 1 operably linked to a regulatory sequence.
7. A vector comprising the polynucleotide of Claim 1.
8. An isolated polynucleotide fragment comprising a nucleotide sequence containing at least 30 nucleotides, wherein the nucleotide sequence containing at least 30 nucleotides is comprised by the polynucleotide of Claim 1.

9. The fragment of Claim 8, wherein the nucleotide sequence containing at least 30 nucleotides contains at least 40 nucleotides.

5 10. The fragment of Claim 8, wherein the nucleotide sequence containing at least 30 nucleotides contains at least 60 nucleotides.

11. A method for transforming a cell comprising transforming a cell with the polynucleotide of Claim 1.

12. A cell comprising the chimeric gene of Claim 6.

10 13. A method for producing a transgenic plant comprising transforming a plant cell with the polynucleotide of Claim 1 and regenerating a plant from the transformed plant cell.

14. A plant comprising the chimeric gene of Claim 6.

15 15. A seed comprising the chimeric gene of Claim 6.

16. An isolated polypeptide having phosphoglucomutase activity, wherein the polypeptide comprises:

20 (a) a first amino acid sequence, wherein the first amino acid sequence and the amino acid sequence of SEQ ID NO:8 have at least 95% identity based on the Clustal alignment method, or
(b) a second amino acid sequence, wherein the second amino acid sequence and the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO: 10 have at least 85% identity based on the Clustal alignment method.

25 17. The polypeptide of Claim 16, wherein the second amino acid sequence and the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO: 10 have at least 90% identity based on the Clustal alignment method.

18. The polypeptide of Claim 16, wherein the second amino acid sequence and the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:10 have at least 95% identity based on the Clustal alignment method.

30 19. The polypeptide of Claim 16, wherein the first amino acid sequence comprises the amino acid sequence of SEQ ID NO:8, and wherein the second amino acid sequence comprises the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:10.

35 20. A method of selecting an isolated polynucleotide that affects the level of expression of a plastidic phosphoglucomutase polypeptide in a plant cell, the method comprising the steps of:

40 (a) constructing the isolated polynucleotide comprising a nucleotide sequence of at least one of 30 contiguous nucleotides derived from the isolated polynucleotide of Claim 1;
(b) introducing the isolated polynucleotide into the plant cell;
(c) measuring the level of the polypeptide in the plant cell containing the polynucleotide; and
(d) comparing the level of the polypeptide in the plant cell containing the isolated polynucleotide with the level of the polypeptide in a plant cell that does not contain the isolated polynucleotide.

45 21. The method of Claim 20 wherein the isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 7, and 9.

22. The method of Claim 20 wherein the isolated polynucleotide comprising a nucleotide sequence of at least 30 contiguous nucleotides contains at least 541 nucleotides.

23. The method of Claim 20 wherein the isolated polynucleotide comprises the nucleotide sequence of SEQ ID NO:15.

24. A method of selecting an isolated polynucleotide that affects the level of expression of a plastidic phosphoglucomutase polypeptide in a plant cell, the method comprising the steps of:

(a) constructing the isolated polynucleotide of Claim 1;
(b) introducing the isolated polynucleotide into the plant cell;

(c) measuring the level of the polypeptide in the plant cell containing the polynucleotide; and
(d) comparing the level of the polypeptide in the plant cell containing the isolated polynucleotide with the level of the polypeptide in a plant cell that does not contain the polynucleotide.

5 25. A method for positive selection of a transformed cell comprising:

(a) transforming a host cell with the chimeric gene of Claim 6; and
(b) growing the transformed host cell under conditions which allow expression of a polynucleotide in an amount sufficient to complement a null mutant to provide a positive selection means,

10 26. The method of Claim 25 wherein the host cell is a plant.

27. The method of Claim 26 wherein the plant cell is a monocot.

15 28. The method of Claim 26 wherein the plant cell is a dicot.

29. A method of altering the level of expression of a plastidic phosphoglucomutase protein in a host cell comprising:

20 (a) transforming a host cell with the chimeric gene of Claim 6; and
(c) growing the transformed host cell produced in step (a) under conditions that are suitable for expression of the chimeric gene wherein expression of the chimeric gene results in production of altered levels of a plastidic phosphoglucomutase polypeptide in the transformed host cell.

25 30. A method for suppressing in a plant the level of expression of a gene encoding a polypeptide having plastidic phosphoglucomutase activity, wherein the method comprises transforming a plant with the fragment of claim 8.

30

35

40

45

50

55

FIGURE 1

SEQ ID NO: 12	1	MAF-----CY-RLDN-FIISAFPKHSNVPLSI-----HHS---SNFPSFKVQNFPER
SEQ ID NO: 13	1	MAF-----CY-RLDN-FIISAFPKHSNVPLSI-----HHS---SNFPSFKVQNFPER
SEQ ID NO: 08	1	MAF-----SC-KLDS-FILSAYKPQNSILPLSI-----QPSFLPSPSSLKPQKLPFR
SEQ ID NO: 04	1	M-----PTM-----HALRLCPLL--
SEQ ID NO: 10	1	TRIARFLPRCKRNTTSPHSPSRSLFSPSPPLLSAWRHCRPPHLGMASHALRILHPLLFS
SEQ ID NO: 02	1	AP-ARY-----RHLSLSQSLSPYL-----QEMAMSVPMTMLHPLVPS
SEQ ID NO: 11	1	MSS-----TYARFDTVFLLSRF-AGAKYSPLWP-----SSSS---SSHSSLLSSGTHLR
	1	60

SEQ ID NO: 12	45	VRYNSAIRATSSSSSTPTT--IA-----EPNDIKINSIPTKPIEGQ
SEQ ID NO: 13	45	VRYNSAIRATSSSSSTPTT--IA-----EPNDIKINSIPTKPIEGQ
SEQ ID NO: 08	47	IRYGSTIRATSSSSSTPSAT--IA-----EPEGIKIKSISIPTKPIDGQ
SEQ ID NO: 04	14	-STIRSTP--PRATAARQ--G---AL-FVARCSAGTPSAQALKISSIPTKPVEGQ
SEQ ID NO: 10	61	AAARPAPLAARPGGGARR---VHRRHSL-AVVRCS---SAQALKIKSISIPTKPVEGQ
SEQ ID NO: 02	37	SKILSPSSSSPAVLVSSRIPLLSRRPNLRESVKATASSTPSTAESIRIKSISIPTKPVEGQ
SEQ ID NO: 11	46	AKPNSRLRSVTGASSSSSGPIA-----GSESEIEIKSISIPTKPIEGQ
	61	120

SEQ ID NO: 12	84	KTGTSGLRKKVVKVFKQENYLANWIQALENSLPPEDYKNGLLVILGGDGRYFNKEAAQIIK
SEQ ID NO: 13	84	KTGTSGLRKKVVKVFKQENYLANWIQALENSLPPEDYKNGLLVILGGDGRYFNKEAAQIIK
SEQ ID NO: 08	86	KTGTSGLRKKVVKVFMQDNYLANWIQALENSLPPEDYKNGLLVILGGDGRYFNKEAAQIIK
SEQ ID NO: 04	63	KTGTSGLRKKVVKVFKQENYLANWIQALENSLPPEDYKNGLLVILGGDGRYFNKEAAQIIK
SEQ ID NO: 10	113	KTGTSGLRKKVVKVFMQDNYLANWIQALENSLPPEDYKNGLLVILGGDGRYFNKEAAQIIK
SEQ ID NO: 02	97	KTGTSGLRKKVVKVFMQDNYLANWIQALENSLPPEDYKNGLLVILGGDGRYFNKEAAQIIK
SEQ ID NO: 11	87	KTGTSGLRKKVVKVFMQDNYLANWIQALENSLPPEDYKDATLVLGGDGRYFNKEAAQIIK
	121	180

FIGURE 1 CONTINUED

SEQ ID NO: 12	144	IAAGNGVGKILVGKEGILSTPAVSAIRKREANGGFIMSASHNP GGPEYDWGIKFNYSSG	181
SEQ ID NO: 13	144	IAAGNGVGKILVGKEGILSTPAVSAIRKREANGGFIMSASHNP GGPEYDWGIKFNYSSG	181
SEQ ID NO: 08	146	IAAGNGVGKILVGKEGILSTPAVSAIRKRAANGGFIMSASHNP GGPEYDWGIKFNYSSG	181
SEQ ID NO: 04	123	IAAGNGVGKILVGKRNGLLSTPAVSAIRKRAANGGFIMSASHNP GGPEYDWGIKFNYSSG	181
SEQ ID NO: 10	173	IAAGNGVGKILVGKRNGLLSTPAVSAIRKRAANGGFIMSASHNP GGPEYDWGIKFNYSSG	181
SEQ ID NO: 02	157	IAAGNGVGKILVGKRNGLLSTPAVSAIRKRAANGGFIMSASHNP GGPEYDWGIKFNYSSG	181
SEQ ID NO: 11	147	IAAGNGVGKILVGQEGILSTPAVSAIRKRAANGGFIMSASHNP GGPEYDWGIKFNYSSG	181
SEQ ID NO: 12	204	QPAPESITDKIYGNTLSISEIKIADIPDVDSLNVGVTKFGSE SVEVIDPVSVDYLELLETV	241
SEQ ID NO: 13	204	QPAPESITDKIYGNTLSISEIKIADIPDVDSLNVGVT KFGSESVEDPVSVDYLELLETV	241
SEQ ID NO: 08	206	QPAPESITDKIYGNTLSISEIKIADIPDVDSLKVGV TNFGSESVEDPVSVDYLELLETV	241
SEQ ID NO: 04	183	QPAPETITDQIYGNTLSISEIKIADIPD TDLSSVGVVSYGDFAEVIDPVSVDYLELLETM ENV	241
SEQ ID NO: 10	233	QPAPETITDQIYGNTLSISEIKIADIPDV DLSLGGVSYGDFTEVIDPVSVDYLELLETM ENV	241
SEQ ID NO: 02	217	QPAPESITDKIYGNTLSISEIKI SDIPDVDSLSSIGVTVNYGNFSEVV DVSVDYLELLETM ENV	241
SEQ ID NO: 11	207	QPAPESITDKIYGNTLSISEIKV AEIPDIDLSRVGTV KGNFSEVIDP ISVDYLELLET M ENV	241
SEQ ID NO: 12	264	FDQLIKSLISRPDFRFT FDAMH AVAGAYATP I FV DKL SAS LDS S N G I P L E D F G H G H P D	301
SEQ ID NO: 13	264	FDQLIKSLISRPDFRFT FDAMH AVAGAYATP I FV DKL GAS L D S I S N G I P L E D F G H G H P D	301
SEQ ID NO: 08	266	FDQLIRGLLSRPDFRF I FDAMH AVTGA YAK P I F V K L G A D P C I L N G V P L E D F G H G H P D	301
SEQ ID NO: 04	243	FDQLIKDLSRPDFRF I FDAMH AVTGA YAK P I F V K L G A D P C I L N G V P L E D F G H G H P D	301
SEQ ID NO: 10	293	FDQLIKGLLSRSDFR F V E K L G A D P C V L N G V P L E D F G H G H P D	301
SEQ ID NO: 02	277	FDQLIKGLLSRSDFR F V E K L G A D P C V L N G V P L E D F G H G H P D	301
SEQ ID NO: 11	267	FDQLIRGLLSRSDFG F M F D A M H A V T G A Y A K P I F V D N L E A K P D S I S N G V P L E D F G H G H P D	301

FIGURE 1 CONTINUED

SEQ ID NO: 12	324	PNLYAKDLVKIMYAENGPDFGAASDGDGRNMILGTSEFFVTPSDSVAVIAANAKEAIPY	324	PNLYAKDLVNIMYAENGPDFGAASDGDGRNMILGTSEFFVTPSDSVAVIAANAKEAIPY	324	PNLYAKDLVNLYAENGPDFGAASDGDGRNMILGRSEFFVTPSDSVAVIAANAREAIPY	326	PNLYAKELVFTMFGTHAPDFGAASDGDGRNMILGKRPFFITPSDSVAVIAANAAQTAIPY	303	PNLYAKELVFTMFGSGAPDFGAASDGDGRNMILGKRRFFVTPSDSVAVIAANAAQAAIPY	353	PNLYAKELVFTMFGSGAPDFGAASDGDGRNMILGKRRFFVTPSDSVAVIAANAAQAAIPY	337	PNLYAKELVVDVWYTTDAPDLGAASDGDGRNMILGRRFFVTPSDSVAVIAANAAQAAIPY	02	PNLYAKDLVVDVWYRDDPDFGAASDGDGRNMVLGNKFFVTPSDSVAVIAANAAQEAIPY	327	PNLYAKDLVVDVWYRDDPDFGAASDGDGRNMVLGNKFFVTPSDSVAVIAANAAQEAIPY	361		420		
SEQ ID NO: 12	384	FKDSIKGLARSMPSTSGLDRVAEKLNLPPFEVPTGKFFGNLMDAGNLSICGEESFGTGS	384	FKDSIKGLARSMPSTSGLDRVAEKLNLPPFEVPTGKFFGNLMDAGNLSICGEESFGTGS	384	FKNGVKGLARSMPSPGALDRVAKKLNLPPFEVPTGKFFGNLMDAGNLSICGEESFGTGS	386	FKNGVKGLARSMPSTSGLDRVAEKLNLPPFEVPTGKFFGNLMDAGNLSICGEESFGTGS	363	FQFGTKGLARSMPSTSGLDRVAEKLNLPPFEVPTGKFFGNLMDAGKLSICGEESFGTGS	10	FQSGPKGLARSMPSTSGLDRVAEKLNLPPFEVPTGKFFGNLMDAGKLSICGEESFGTGS	413	FQAGPKGLARSMPSTSGLDRVAEKLNLPPFEVPTGKFFGNLMDAGKLSICGEESFGTGS	02	FQAGPKGLARSMPSTSGLDRVAEKLNLPPFEVPTGKFFGNLMDAGKLSICGEESFGTGS	397	FQAGPKGLARSMPSTSGLDRVAEKLNLPPFEVPTGKFFGNLMDAGKLSICGEESFGTGS	11	FQAGPKGLARSMPSTSGLDRVAEKLNLPPFEVPTGKFFGNLMDAGKLSICGEESFGTGS	421		480
SEQ ID NO: 12	444	DHIREKDGIVAVLAWLSILAHRNKDTKPGEKLVSVSDVVKEHWATYGRNFFSRYDYECE	444	DHIREKDGIVAVLAWLSILAHRNKDTKPGEKLVSVSDVVKEHWATYGRNFFSRYDYECE	444	DHIREKDGIVAVLAWLSILAHRNKDTKPGEKLVSVSDVVKEHWATYGRNFFSRYDYECE	08	DHIREKDGIVAVLAWLSILAHRNKDTKPGEKLVSVSDVVKEHWATYGRNFFSRYDYECE	446	DHIREKDGIVAVLAWLSILAHRNKDTKPGEKLVSVSDVVKEHWATYGRNFFSRYDYECE	04	DHIREKDGIVAVLAWLSILAHRNKDTKPGEKLVSVSDVVKEHWATYGRNFFSRYDYECE	10	DHIREKDGIVAVLAWLSILAHRNKDTKPGEKLVSVSDVVKEHWATYGRNFFSRYDYECE	02	DHIREKDGIVAVLAWLSILAHRNKDTKPGEKLVSVSDVVKEHWATYGRNFFSRYDYECE	11	DHIREKDGIVAVLAWLSILAHRNKDTKPGEKLVSVSDVVKEHWATYGRNFFSRYDYECE	447	DHIREKDGIVAVLAWLSILAHRIKDKKKPGEKLVSVADVNEYWATYGRNFFSRYDYECE	481		540

FIGURE 1 CONTINUED

SEQ ID NO: 12	504	SEGANKMIEYLRELLSKSKPGDKYGSYVVLQFADDFTYTDPVDGSVVSKQGVRFVETDGSR	541
SEQ ID NO: 13	504	SEGANKMIEYLRELLSKSKPGDKYGSYVVLQFADDFTYTDPVDGSVVSKQGVRFVETDGSR	
SEQ ID NO: 08	506	SEGANKMIEYLRDILSKSKPGDQYGSYVVLQFADDFTYTDPVDGSVVSKQGVRFVETDGSR	
SEQ ID NO: 04	483	SHSANQMMMDHLRDVMANSKPKGEKYGNYLQFADDFSYTDPVDGSTVSKQGLRFVFTDGSR	
SEQ ID NO: 10	533	SESAKMMEHLRDLVIAKSXPGEKYGNYLQFADDFSYTDPVDGSTVSKQGLRFVFTDGSR	
SEQ ID NO: 02	517	SEGANKMMQHLRDFIISTSKPKGEQYGNYTLQFSDDESYTDPVDGSVASKQGGLRFVFTDGSR	
SEQ ID NO: 11	507	SEGANKMIEYLRDIVAKSKAGENYGNYVLIQFADDFSYKDPVDGSVASKQGVRFVFTDGSR	
		600	
SEQ ID NO: 12	564	IIYRLSGTGGSAGATVRYIEQFEPDVSKHDVDAQIAALKPLIDALSVSKLKDFTGREKPT	601
SEQ ID NO: 13	564	IIYRLSGTGGSAGATVRYIEQFEPDVSKHDVDAQIAALKPLIDALSVSKLKDFTGREKPT	
SEQ ID NO: 08	566	IIYRLSGTGGSAGATVRYIEQFEPDVSKHDVDAQIAALKPLIDALSVSKLKDFTGREKPT	
SEQ ID NO: 04	543	IIIFRLSGTGGSAGATIRIYIEQFESDISKHSLSDAQTALKPLIDALSVSKLKDFTGREKPT	
SEQ ID NO: 10	593	IIIFRLSGTGGSAGATIRIYIEQFESDASKHDLDAQIAALKPLIDALSVSKLKDFTGRDKPT	
SEQ ID NO: 02	577	VIYRLSGTGGSAGATIRIYIEQFEPDVSKHDVDAQALKPLIDALSIISKLKEFTGREGKPT	
SEQ ID NO: 11	567	IIYRLSGNGSAGATVRYIEQFEPDVSKHDVDAQIAKPLIDALSVSKLKEFTGREGKPT	
		660	
SEQ ID NO: 12	624	***	661
SEQ ID NO: 13	624	VIT	663
SEQ ID NO: 08	626	VIT	
SEQ ID NO: 04	603	VIT	
SEQ ID NO: 10	653	VIT	
SEQ ID NO: 02	637	VIT	
SEQ ID NO: 11	627	VIT	